Supporting Information-1 (SI and NMR spectra I) for:

Total Synthesis of Agelagalastatin

Yong Joo Lee, Bo-Young Lee, Heung Bae Jeon, and Kwan Soo Kim*

Center for Bioactive Molecular Hybrids and Department of Chemistry, Yonsei University, Seoul 120-749, Korea.

kwan@yonsei.ac.kr

General Methods. All reactions were conducted under a positive pressure of dry argon with dry, freshly distilled solvents unless otherwise noted. All reagents were purchased from commercial suppliers and used without further purification unless otherwise noted. Dichloromethane and acetonitrile were distilled from calcium hydride and DMF was distilled from barium oxide. Ethyl acetate and toluene were distilled. Flash column chromatography was performed employing 230-400 mesh silica gel. Thin-layer chromatography was performed using silica gel 60 F254 precoated plates (0.25 mm thickness) with a fluorescent indicator. Visualization on TLC was achieved by UV light (254 nm) and a typical TLC indication solution (cerium sulfate / molybdic acid solution). NMR spectra were recorded on a 250 or 500 MHz NMR spectrometer. Chemical shifts were reported in parts per million (ppm) downfield from tetramethylsilane (TMS). IR spectra were obtained on a Nicolet Impact 400 spectrometer. MALDI-TOF was performed by the 4700 proteomics analyzer, HRMS-FAB by JEOL, JMS-AX505WA, HP 5890 Series II.

SI-Scheme 1. Preparation of monosaccharide **7**.

2'-(Benzyloxycarbonyl)benzyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (S2). To a stirred solution of 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide (S1) (5.0 g, 12.16 mmol) in acetonitrile (20 mL) at 0 °C were added mercury (II) bromide (5.26 g, 14.59 mmol), mercury (II) cyanide (3.69 g, 14.61 mmol), and benzyl 2-hydroxymethylbenzoate (18) (4.4 g, 18.16 mmol). After stirring at 0 °C for further 30 min, the reaction mixture was filtered and the filtrate was concentrated. The resulting oil was dissolved in CH_2Cl_2 (50 mL) and the solution was washed with saturated aqueous $NaHCO_3$ (2 × 50 mL) and brine (50 mL). The organic layer was dried over $MgSO_4$ and concentrated in vacuo and the residue was purified by silica gel flash column chromatography (hexane/EtOAc, 2:1, v/v) to afford the title compound S2 (4.74 g, 8.28 mmol,

86%) as a colorless oil.: $R_f = 0.25$ (hexane/EtOAc, 2:1, v/v); IR (CHCl₃ film) 1225, 1713, 1751 cm⁻¹; $[\alpha]_D^{20} - 27.7$ (c 1.3, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 2.00 (s, 3 H), 2.03 (s, 3 H), 2.06 (s, 3 H), 2.17 (s, 3 H), 3.91 (t, J = 6.7 Hz, 1 H), 4.11–4.19 (m, 2 H), 4.59 (d, J = 7.9 Hz, 1 H), 5.01–5.10 (m, 2 H), 5.31–5.42 (m, 5 H), 7.31–7.65 (m, 8 H), 8.03 (d, J = 7.8 Hz); ¹³C NMR (63 MHz, CDCl₃) δ 20.7, 20.8(2), 20.9, 61.2, 66.9, 67.1, 69.1, 69.8, 70.8, 71.0, 101.1, 127.3, 127.5, 128.3, 128.5, 128.8, 130.8, 132.8, 135.9, 139.9, 166.6, 169.6, 170.3, 170.4, 170.5. Anal. calcd for $C_{29}H_{32}O_{12}$: C, 60.83; H, 5.63. Found: C, 60.81; H, 5.72.

2′-(Benzyloxycarbonyl)benzyl β-D-galactopyranoside (S3). To a solution of compound S2 (3.2 g, 5.59 mmol) in MeOH (100 mL) was added NaOMe (54 mg, 1.0 mmol.) at 0 °C. After stirring at room temperature for 30 min, the reaction mixture was neutralized with DOWEX CCR-3 (H⁺ mode), filtered through Celite®, and concentrated in vacuo. The residue was purified by recrystallization (n-hexane/MeOH) to afford the title compound S3 (2.15 g, 5.32 mmol, 95%) as a white solid.: m.p.= 92–93 °C; R_f = 0.33 (CHCl₃/MeOH, 9:1, v/v); IR (KBr) 1256, 1714, 3353 cm⁻¹; $[\alpha]_D^{20}$ –18.8 (*c* 0.5, DMF); ¹H NMR (500 MHz, DMSO-d₆ + H₂O) δ 3.32 (dd, J = 3.0, 9.6 Hz, 1 H), 3.37 (t, J = 5.8 Hz, 1 H), 3.42 (t, J = 8.6 Hz, 1 H), 3.49 (dd, J = 6.1, 10.5 Hz, 1 H), 3.54 (dd, J = 6.4, 10.8 Hz, 1 H), 3.67 (brs, 1 H), 4.21 (d, J = 7.6 Hz, 1 H), 4.91 and 5.10 (ABq, J = 14.8 Hz, 2 H), 5.29 (s, 2 H), 7.31–7.59 (m, 7 H), 7.81 (d, J = 7.7 Hz, 1 H), 7.86 (d, J = 7.7 Hz, 1 H); ¹³C NMR (63 MHz, DMSO-d₆ + H₂O) δ 60.8, 66.9, 68.3, 68.5, 71.1, 73.7, 75.5, 103.6, 127.7, 128.1, 128.3, 128.6, 128.7, 129.1, 130.4, 133.0, 136.4, 140.5, 166.9. Anal. calcd for C₂₁H₂₄O₈: C, 62.37; H, 5.98. Found: C, 62.19; H, 5.88.

2'-(Benzyloxycarbonyl)benzyl 4,6-*O*-benzylidene-β-D-galactopyranoside (S4). A solution of the compound S3 (1.0 g, 2.47 mmol) and benzaldehyde dimethylacetal (408 μL, 2.72 mmol) in the presence of camphor sulfonic acid (172 mg, 0.74 mmol) in DMF (20 mL) was stirred at 60 °C for 1 h 40 min. After quenched with triethylamine (1 mL), the reaction mixture was extracted with EtOAc (3 × 50 mL). The combined organic layer was washed with saturated aqueous NH₄Cl (2 × 50 mL) , brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by recrystallization (n-hexane/EtOAc) to afford the title compound S4 (2.80 g, 70%) as a white solid.: m.p.= 177–178 °C; $R_f = 0.15$ (hexane/EtOAc/CH₂Cl₂, 2:4:4, v/v); IR (KBr) 1256, 1715, 3378 cm⁻¹; [α]_D²⁰ –32.0 (*c* 0.5, DMF); ¹H NMR (250 MHz, DMSO-d₆) δ 3.50–3.52 (m, 3 H), 4.05–4.09 (m, 3 H), 4.34–4.37 (m, 1 H), 4.96–4.98 (m, 1 H), 4.97 and 5.17 (ABq, J = 15.0 Hz, 2 H), 5.18–5.21 (m, 1 H), 5.34 (s, 2 H), 5.57 (s, 1 H), 7.35–7.65 (m, 13 H), 7.92 (d, J = 7.7 Hz, 1 H); ¹³C NMR (63 MHz, DMSO-d₆) δ 66.0,66.3, 67.8, 68.6, 70.2, 71.9, 76.0, 99.8, 103.0, 126.3, 127.1, 127.6, 127.9, 128.1, 128.5, 130.0, 132.5, 136.0, 138.6, 140.3, 166.1. Anal. calcd for C₂₈H₂₈O₈: C, 68.28; H, 5.73. Found: C, 68.21; H, 5.87.

2'-(Benzyloxycarbonyl)benzyl 4,6-*O*-benzylidene-3-*O*-*p*-methoxybenzyl-β-D-galactopyranoside (**S6).** To a solution of compound **S4** (3.63 g, 7.37 mmol) in MeOH (30 mL) was added Bu₂SnO (2.75 g, 11.05 mmol). The resulting solution was heated to reflux for 3 h. The solvent was removed and then concentrated in vacuo. The residue was dissolved in DMF (20 mL), then *p*-methoxybenzyl chloride (1.5 mL, 11.06 mmol) and Bu₄NI (4.08 g, 11.04 mmol) were added. The reaction mixture was stirred at 60 °C for 3 h. The reaction mixture was diluted with EtOAc (50 mL) and quenched with saturated aqueous NH₄Cl (7 mL). The combined organic layer was washed with saturated

aqueous NH₄Cl (2 × 50 mL) and brine (50 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by recrystallization (n-hexane/EtOAc) to afford the title compound **S6** (3.84 g, 6.27 mmol, 85%) as a white solid.: m.p.= 132–133 °C; R_f = 0.33 (hexane/EtOAc, 1:1, v/v); IR (CHCl₃ film) 1255, 1713, 3207 cm⁻¹; $[\alpha]_D^{20}$ +3.7 (*c* 0.6, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 2.77 (brs, 1 H), 3.30 (brs, 1 H), 3.48 (dd, J = 3.0, 9.5 Hz, 1 H), 3.77 (s, 3 H), 3.97–4.08 (m, 3 H), 4.28 (d, J = 12.2 Hz, 1 H), 4.42 (d, J = 7.8 Hz, 1 H), 4.69 (s, 2 H), 5.09 and 5.28 (ABq, J = 13.6 Hz, 2 H), 5.32 (s, 2 H), 5.45 (s, 1 H), 6.85 (d, J = 8.3 Hz, 2 H), 7.23–7.53 (m, 14 H), 7.72 (d, J = 7.6 Hz, 1 H), 7.97 (d, J = 7.7 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 55.3, 66.8, 66.9, 69.3, 70.2, 71.2, 73.3, 78.9, 101.1, 102.8, 113.9, 126.5, 127.4, 128.1, 128.25, 128.3, 128.7, 128.9, 129.5, 130.3, 130.6, 132.6, 135.9, 137.9, 139.8, 159.3, 167.1. Anal. calcd for C₃₆H₃₆O₉: C, 70.57; H, 5.92. Found: C, 70.51; H, 6.02.

2'-(Benzyloxycarbonyl)benzyl 2-*O*-benzyl-4,6-*O*-benzylidene-3-*O*-*p*-methoxybenzyl-β-D-galactopyranoside (S7). To a solution of S6 (2.18 g, 3.56 mmol) and BnBr (636 μL, 5.35 mmol) in DMF (10 mL) was added NaH (60%, 214 mg, 5.35 mmol) at 0 °C and then the ice bath was removed. After stirring at room temperature for 2 h, the reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layer was washed with saturated aqueous NH₄Cl (50 mL) and brine (50 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 1:1, v/v) to afford the title compound S7 (2.2 g, 3.13 mmol, 88%) as a white solid.: m.p.= 129–130 °C; R_f = 0.6 (hexane/EtOAc, 1:1, v/v); IR (CHCl₃ film) 1255, 1713 cm⁻¹; $[\alpha]_D^{20}$ +1.0 (*c* 1.0, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 3.28 (brs, 1 H), 3.56 (dd, J = 3.6, 9.6 Hz, 1 H), 3.78 (s, 3 H), 3.92–4.02 (m, 2

H), 4.09 (d, J = 3.4 Hz, 1 H), 4.30 (d, J = 12.2 Hz, 1 H), 4.52 (d, J = 7.8 Hz, 1 H), 4.71–4.77 (m, 2 H), 4.85 and 4.95 (ABq, J = 10.8 Hz, 2 H), 5.13 and 5.41 (ABq, J = 15.1 Hz, 2 H), 5.29 (s, 2 H), 5.00 (s, 1 H), 6.83 (d, J = 8.6 Hz, 2 H), 7.22–7.59 (m, 19 H), 7.84 (d, J = 7.7 Hz, 1 H), 8.01 (d, J = 7.8 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 55.4, 66.6, 66.7, 69.3, 71.7, 74.0, 75.5, 78.7, 79.1, 101.4, 103.2, 113.8, 126.6, 126.9, 127.4, 127.6, 128.2, 128.21, 128.30, 128.33, 128.7, 129.0, 129.5, 130.5, 130.6, 132.7, 136.1, 138.0, 138.9, 140.9, 159.3, 166.7. Anal. calcd for C₄₃H₄₂O₉: C, 73.49; H, 6.02. Found: C, 73.42; H, 6.17.

2'-(Benzyloxycarbonyl)benzyl 2-*O*-benzyl-4,6-*O*-benzylidene-β-D-galactopyranoside (7). To a solution of compound **S7** (143 mg, 0.203 mmol) in CH₂Cl₂ / H₂O (9.5 mL, 18:1, v/v) was added DDQ (60 mg, 0.264 mmol). After stirring at 0 °C for 1 h, the reaction mixture was quenched with NaHCO₃ (5 mL) and extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layer was washed with saturated aqueous NaHCO₃ (2 × 20 mL) and brine (20 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 1:1, v/v) to afford the title compound **7** (109 mg, 0.187 mmol, 92%) as a white solid.: m.p.= 164–165 °C; R_f = 0.3 (hexane/EtOAc, 1:1, v/v); IR (CHCl₃ film) 1262, 1709, 3403 cm⁻¹; [α]_D²⁰ –12.2 (*c* 0.6, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 2.51–2.54 (m, 1 H), 3.43 (s, 1 H), 3.71–3.80 (m, 2 H), 4.07 and 4.32 (ABq, J = 12.4 Hz, 2 H), 4.22 (s, 1 H), 4.55 (d, J = 7.3 Hz, 1 H), 4.78 and 5.01 (ABq, J = 11.2 Hz, 2 H), 5.15 and 5.41 (ABq, J = 14.8 Hz, 2 H), 5.31 (s, 2 H), 5.56 (s, 1 H), 7.25–7.53 (m, 17 H), 7.82 (d, J = 7.7 Hz, 1 H), 8.02 (d, J = 7.7 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 66.7, 66.8, 69.3, 69.4, 75.2, 75.7, 79.6, 101.5, 103.1, 126.6, 127.1, 127.6, 127.8, 128.2, 128.3, 128.5, 128.7, 129.3, 130.7, 132.7, 136.1,137.7, 138.6, 140.7, 166.8. Anal. calcd for C₃₅H₃₄O₈: C, 72.15; H, 5.88.

Found: C, 72.07; H, 5.95.



2'-(Benzyloxycarbonyl)benzyl 2,3,5,6-tetra-O-acetyl-β-D-galactofuranoside (9). A solution of Dgalactofuranosyl pentaacetate (8) (3.90 g, 10.0 mmol), thionyl chloride (5 mL), and acetic acid (2 mL) in CH₂Cl₂ (20 mL) was stirred at 0 °C for 18 h. Removal of the solvent and then concentration in vacuo gave crude 2,3,5,6-tetra-O-acetyl-D-galactofuranosyl chloride. A solution of the crude galactofuranosyl chloride, mercury (II) bromide (4.3 g, 11.93 mmol), mercury (II) cyanide (3.03 g, 11.99 mmol), and benzyl 2-hydroxymethylbenzoate (18) (2.91 g, 12.01 mmol) in acetonitrile (30 mL) was stirred at room temperature for 30 min, and the reaction mixture was filtered through Celite®, then the filtrate was concentrated. The resulting oil was dissolved in CH₂Cl₂(50 mL) and the solution was washed with saturated aqueous NaHCO₃ (2 × 50 mL) and brine (50 mL). The organic layer was dried over MgSO₄, concentrated in vacuo, and the residue was purified by silica gel flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound 9 (4.35 g, 7.60 mmol, 76%) as a colorless oil.: $R_f = 0.35$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1225, 1370, 1747 cm⁻¹; $[\alpha]_D^{20}$ -40.4 (c 1.3, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 2.02 (s, 3 H), 2.08 (s, 3 H), 2.10 (s, 3 H), 2.13 (s, 3 H), 4.20 (dd, J = 7.1, 11.8 Hz, 1 H), 4.28–4.35 (m, 2 H), 4.99 and 5.15 (ABq, J = 14.5 Hz, 2 H), 5.05 (dd, J = 1.5, 5.8 Hz, 1 H), 5.18-5.20 (m, 2 H), 5.33 (s, 2 H),5.38-5.44 (m, 1 H), 7.30-7.56 (m, 7 H), 7.67 (d, J=7.7 Hz, 1 H), 8.00 (d, J=7.8 Hz, 1 H); 13 C NMR (63 MHz, CDCl₃) δ 20.5(2), 20.6, 20.7, 62.5, 66.6, 67.2, 69.2, 76.5, 80.2, 81.1, 105.2, 127.1, 127.6, 127.9, 128.0, 128.1, 128.5, 130.5, 132.3, 135.8, 139.7, 166.3, 169.4, 169.8, 169.9, 170.3. Anal. calcd for C₂₉H₃₂O₁₂: C, 60.83; H, 5.63. Found: C, 60.87; H, 5.55.



2'-(Benzyloxycarbonyl)benzyl β-D-galactofuranoside (10). To a solution of compound 9 (4.4 g, 7.68 mmol) in MeOH (100 mL) was added NaOMe (54 mg, 1.0 mmol) at 0 °C. After stirring at room temperature for 30 min, the reaction mixture was neutralized with DOWEX CCR-3 (H⁺ mode), filtered through Celite®, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (CHCl₃/MeOH, 9:1, v/v) to afford the title compound 10 (2.86 g, 7.07 mmol, 92%) as a white solid.: m.p.= 77–78 °C; R_f = 0.35 (CHCl₃/MeOH, 9:1, v/v); IR (CHCl₃ film) 1258, 1711, 3376 cm⁻¹; $[\alpha]_D^{20}$ –75.1 (*c* 2.6, CHCl₃); ¹H NMR (250 MHz, CD₃OD) δ 3.59–3.62 (m, 2 H), 3.71–3.74 (m, 1 H), 3.97–4.07 (m, 3 H), 4.90 and 5.08 (ABq, J = 14.1 Hz, 2 H), 5.00 (brs, 1 H), 5.33 (s, 2 H), 7.30–7.58 (m, 7 H), 7.70 (d, J = 7.4 Hz, 1 H), 7.92 (dd, J = 1.2, 7.8 Hz, 1 H); ¹³C NMR (63 MHz, CD₃OD) δ 64.5, 67.8, 68.6, 72.3, 78.8, 83.5, 84.4, 109.3, 128.3, 129.3, 129.35, 129.6, 131.3, 133.4, 137.5, 141.5, 168.3. Anal. calcd for C₂₁H₂₄O₈: C, 62.37; H, 5.98. Found: C, 62.30; H, 5.98.



2'-(Benzyloxycarbonyl)benzyl 2,3,5,6-tetra-*O***-benzyl-β-D-galactofuranoside (11).** To a solution of **10** (615 mg, 1.52 mmol) and BnBr (815 μL, 6.85 mmol) in DMF (10 mL) was added NaH (60%,

274 mg, 6.85 mmol) at 0 °C and then the ice bath was removed. After stirring at room temperature for 1 h, the reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layer was washed with saturated aqueous NH₄Cl (50 mL) and brine (50 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 7:1, v/v) to afford the title compound **11** (977 mg, 1.28 mmol, 84%) as a colorless oil.: $R_f = 0.55$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1258, 1712 cm⁻¹; $[\alpha]_D^{20} - 60.5$ (*c* 0.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 3.62–3.70 (m, 2 H), 3.77–3.80 (m, 1 H), 4.05–4.07 (m, 1 H), 4.10 (brs 1 H), 4.17–4.19 (m, 1 H), 4.32 (d, J = 11.6 Hz, 1 H), 4.44–4.56 (m, 6 H), 4.72 (d, J = 11.6 Hz, 1 H), 4.97 and 5.11 (ABq, J = 14.3 Hz, 2 H), 5.20 (s, 1 H), 5.30 (s. 2 H), 7.21–7.48 (m, 27 H), 7.64 (d, J = 7.6 Hz, 1 H), 7.96 (d, J = 7.6 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 66.8, 67.5, 71.2, 71.9, 72.2, 73.4, 73.5, 76.5, 81.3, 83.0, 88.6, 105.9, 127.1, 127.7, 127.8, 127.9, 128.0, 128.2, 128.4, 128.7, 130.7, 132.4, 136.1, 137.8, 138.1, 138.5, 138.6, 140.7, 188.6. Anal. calcd for C₄₉H₄₈O₈: C, 76.94; H, 6.33. Found: C, 76.92; H, 6.30.



2'-Carboxybenzyl 2,3,5,6-tetra-*O***-benzyl-**β**-D-galactofuranoside (5).** Compound **11** (670 mg, 0.88 mmol) was stirred under hydrogen atmosphere using a balloon in the presence of Pd/C (10%, 93 mg) and ammonium acetate (67 mg, 0.87 mmol) in MeOH–EtOAc (1:1 v/v, 10 mL) at room temperature for 1 h. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 1:1, v/v) to afford the title compound **5** (564 mg, 0.84 mmol, 95%) as a colorless


oil.: $R_f = 0.50$ (hexane/EtOAc, 1:1, v/v); IR (CHCl₃ film) 1695, 3157 cm⁻¹; $[\alpha]_D^{20}$ –71.5 (c 0.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 3.65–3.71 (m, 2 H), 3.77–3.82 (m, 1 H), 4.08–4.09 (m, 1 H), 4.14 (brs, 1 H), 4.23 (dd, J = 3.0, 6.9 Hz, 1 H), 4.33 (d, J = 11.7 Hz, 1 H), 4.45–4.49 (m, 4 H), 4.53 and 4.58 (ABq, J = 11.9 Hz, 2 H), 4.71 (d, J = 11.7 Hz, 1 H), 4.98 and 4.14 (ABq, J = 14.4 Hz, 2 H), 5.25 (s, 1 H), 7.21–7.31 (m, 21 H), 7.50 (t, J = 7.4 Hz, 1 H), 7.68 (d, J = 7.7 Hz, 1 H), 8.04 (d, J = 7.7 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 67.5, 70.8, 71.9, 72.1, 73.3, 73.4, 76.3, 81.2, 82.9, 88.5, 105.9, 127.2, 127.6, 127.8, 127.9, 128.0, 128.1, 128.4, 131.5, 133.2, 137.7, 138.0, 138.3, 138.5, 141.3, 172.3. Anal. calcd for $C_{42}H_{42}O_8$: C, 74.76; H, 6.27. Found: C, 74.76; H, 6.31.



2'-(Benzyloxycarbonyl)benzyl 5,6-*O*-isopropylidene-β-D-galactofuranoside (12). A solution of compound 10 (2.03 g, 5.02 mmol) and 2,2-dimethoxypropane (740 μL, 6.02 mmol) in the presence of camphor sulfonic acid (12 mg, 0.05 mmol) in DMF (20 mL) was stirred at room temperature for 1 h. After quenched with triethylamine (1 mL), the reaction mixture was extracted with EtOAc (3 × 50 mL). The combined organic layer was washed with saturated aqueous NH₄Cl (2 × 50 mL), brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 1:3, v/v) to afford the title compound 12 (2.80 g, 70%) as a white solid.: m.p.= 62–63 °C; R_f = 0.48 (hexane/EtOAc, 1:3, v/v); IR (CHCl₃ film) 1258, 1713, 3430 cm⁻¹; [α]_D²⁰ –53.8 (*c* 1.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 1.41 (s, 3 H), 1.43 (s, 3 H), 3.18 (d, J = 11.6 Hz, 1 H), 4.01–4.14 (m, 6 H), 4.36 (t, J = 7.1 Hz, 1 H), 4.83 (d, J = 13.1 Hz, 1 H), 5.16–5.19 (m, 2 H), 5.31–5.37 (m, 2 H), 7.35–7.55 (m, 7 H), 8.00 (d, J = 7.7 Hz, 1 H); ¹³C NMR

(125 MHz, CDCl₃) δ 25.7, 25.8, 65.9, 67.0, 68.0, 75.9, 78.5, 78.9, 85.7, 108.6, 110.3, 127.9, 128.4, 128.5, 128.8, 129.0, 131.0, 132.7, 135.9, 139.4, 166.8. Anal. calcd for C₂₄H₂₈O₈: C, 64.85; H, 6.35. Found: C, 64.90; H, 6.26.






2'-(Benzyloxycarbonyl)benzyl

2-*O-t*-buthyldimethylsilyl-5,6-*O*-isopropylidene-β-D-

galactofuranoside (13) and 2'-(Benzyloxycarbonyl)benzyl 3-*O*-t-buthyldimethylsilyl-5,6-*O*-isopropylidene-β-D-galactofuranoside (14). A solution of compound 12 (212 mg, 0.48 mmol), imidazole (97 mg, 1.42 mmol), and TBDMSCl (79 mg, 0.52 mmol) in DMF (4 mL) was stirred at room temperature for 4 h. The reaction mixture was quenched with saturated aqueous NH₄Cl (5 mL), extracted with EtOAc (2 × 30 mL). The combined organic layer was washed with saturated aqueous NH₄Cl (2 × 30 mL) and brine (30 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound 13 (220 mg, 0.43 mmol, 82 %) and compound 14 (21 mg, 0.04 mmol, 8%). Compound 13: colorless oil, R_f = 0.35 (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1255, 1717, 3484 cm⁻¹; [α]_D²⁰ −53.4 (*c* 0.9, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.11 (s, 3 H), 0.13 (s, 3 H), 0.91 (s, 9 H), 1.40 (s, 3 H), 1.49 (s, 3 H), 3.05 (d, J = 10.2 Hz, 1 H), 3.72 (d, J = 9.7 Hz, 1 H), 3.91 (t, J = 7.3 Hz, 1 H), 4.04 (t, J = 7.6 Hz, 1 H), 4.14 (d, J = 5.3 Hz, 1 H), 4.17 (s, 1 H), 4.31–4.34 (m, 1 H), 4.88 and 5.20 (ABq, J = 13.2 Hz, 2 H), 5.11 (s, 1 H), 5.35 (s, 2 H), 7.33–7.56 (m, 8 H), 7.99 (d, J = 7.5 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ -4.9, 17.9, 25.2, 25.6, 26.7, 65.6, 66.7, 67.7, 76.4, 78.8, 81.3, 87.8, 107.9, 109.7, 127.5, 128.2, 128.6, 128.8, 130.7, 132.3, 135.8, 139.5, 166.6. Anal. calcd for

C₃₀H₄₂O₈Si: C, 64.49; H, 7.58. Found: C, 64.41; H, 7.63. Compound **14**: colorless oil, $R_f = 0.43$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1255, 1717, 3438 cm⁻¹; $[\alpha]_D^{20}$ –50.0 (*c* 0.3, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.12 (s, 3 H), 0.15 (s, 3 H), 0.92 (s, 9 H), 1.40 (s, 3 H), 1.42 (s, 3 H), 3.45 (d, J = 10.1 Hz, 1 H), 3.95–4.03 (m, 4 H), 4.12 (s, 1 H), 4.22 (t, J = 6.6 Hz, 1 H), 5.00 and 5.16 (ABq, J = 15.0 Hz, 2 H), 5.14 (s, 1 H), 5.33 (s, 2 H), 7.25–7.49 (m, 7 H), 7.82 (d, J = 7.7 Hz, 1 H), 7.99 (d, J = 7.6 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ -4.8, -4.4, 18.1, 25.8, 65.8, 66.8, 67.5, 76.2, 79.9, 80.8, 85.2, 109.2, 110.0, 126.7, 127.6, 128.4, 128.7, 130.5, 132.5, 136.1, 141.6, 166.8. Anal. calcd for C₃₀H₄₂O₈Si: C, 64.49; H, 7.58. Found: C, 64.43; H, 7.67.



2'-(Benzyloxycarbonyl)benzyl 3-*O*-benzyl-2-*O*-*t*-buthyldimethylsilyl-5,6-*O*-isopropylidene-β-D-galactofuranoside (15). To a solution of 13 (400 mg, 0.716 mmol) and BnBr (103 μL, 0.866 mmol) in DMF (10 mL) was added NaH (60%, 35 mg, 0.875 mmol) at 0 °C and then the ice bath was removed. After stirring at room temperature for 1 h, the reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layer was washed with saturated aqueous NH₄Cl (50 mL) and brine (50 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 9:1, v/v) to afford the title compound 15 (441 mg, 0.680 mmol, 95%) as a colorless oil.: $R_f = 0.25$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1282, 1728 cm⁻¹; $[\alpha]_D^{20}$ +40.7 (*c* 0.7, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.13 (s, 3 H), 0.17 (s, 3 H), 0.95 (s, 9 H), 1.41 (s, 3 H), 1.46 (s, 3 H), 3.78 (d, *J* = 3.8 Hz, 1 H), 3.87–3.95 (m, 2 H), 4.20 (t, *J* = 5.5 Hz, 1 H), 4.29 (dd, *J* = 6.4, 12.9 Hz, 1 H), 4.43

(s, 1 H), 4.61 and 4.74 (ABq, J = 11.7 Hz, 2 H), 5.08 (s, 1 H), 5.09 and 5.23 (ABq, J = 14.8 Hz, 2 H), 5.38 (s, 2 H), 7.35–7.53 (m, 12 H), 7.78 (d, J = 7.6 Hz, 1 H), 8.03 (d, J = 7.6 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ -4.8, -4.6, 18.0, 25.3, 25.8, 26.6, 65.6, 66.7, 67.3, 72.2, 76.1, 81.1, 83.6, 86.3, 108.3, 109.7, 126.9, 127.8, 127.9, 128.3, 128.5, 128.7, 130.6, 132.4, 136.1, 137.9, 141.0, 166.7. Anal. calcd for C₃₇H₄₈O₈Si: C, 68.49; H, 7.46. Found: C, 68.43; H, 7.54.



2'-(Benzyloxycarbonyl)benzyl 3-*O*-benzyl-5,6-*O*-isopropylidene-β-D-galactofuranoside (16). A solution of compound 15 (420 mg, 0.647 mmol) and Bu₄NF (1.0M, 1 mL, 1 mmol) in THF (3 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound 16 (339 mg, 0.634 mmol, 98 %) as a colorless oil.: $R_f = 0.25$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1260, 1714, 3434 cm⁻¹; $[\alpha]_D^{20}$ –72.8 (*c* 1.2, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.36 (s, 3 H), 1.41 (s, 3 H), 3.64 (d, J = 10.1 Hz, 1 H), 3.92–3.96 (m, 3 H), 4.15–4.20 (m, 2 H),4.29 (d, J = 10.0 Hz, 1 H), 4.54 and 4.70 (ABq, J = 11.8 Hz, 2 H), 4.99 and 5.18 (ABq, J = 14.8 Hz, 2 H), 5.16 (s, 1 H), 5.30 (s, 2 H), 7.23–7.42 (m, 12 H), 7.72 (d, J = 7.7 Hz, 1 H), 7.96 (d, J = 7.7 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 25.7, 25.8, 65.5, 66.6, 67.3, 71.9, 76.3, 77.4, 82.8, 86.0, 108.8, 109.8, 126.7, 127.6, 127.8, 128.2, 128.4, 128.6, 130.4, 132.4, 135.9, 137.7, 141.0, 166.7. Anal. calcd for $C_{31}H_{34}O_8$: C, 69.65; H, 6.41. Found: C, 69.59; H, 6.22.



2'-(Benzyloxycarbonyl)benzyl


3-*O*-benzyl-5,6-*O*-isopropylidene-2-*O*-pivaloyl-β-D-


galactofuranoside (17). To a solution of compound 16 (3.4 g, 6.36 mmol) and Et₃N (1.8 mL) in CH₂Cl₂ (10 mL) were added pivaloyl chloride (940 μL, 7.63 mmol) and DMAP (233 mg, 1.91 mmol). After stirring at room temperature for 1 h, the reaction mixture was quenched with aqueous NH₄Cl (5 mL) and extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layer was washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound 17 (3.89 g, 6.29 mmol, 99 %) as a colorless oil.: $R_f = 0.53$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1262, 1728 cm⁻¹; [α]_D²⁰ –89.8 (*c* 2.1, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.22 (s, 9 H), 1.34 (s, 3 H), 1.39 (s, 3 H), 3.72–3.86 (m, 3 H), 4.14–4.22 (m, 2 H), 4.56 and 4.82 (ABq, J = 11.9 Hz, 2 H), 5.06 and 5.19 (ABq, J = 14.7 Hz, 2 H), 5.17 (s, 1 H), 5.28 (s, 1 H), 5.31 (s, 2 H), 7.24–7.52 (m, 12 H), 7.73 (d, J = 7.7 Hz, 1 H), 7.98 (d, J = 7.7 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 25.4, 26.4, 27.0, 38.7, 65.4, 66.7, 67.2, 72.1, 75.8, 80.6, 83.6, 83.7, 105.9, 109.8, 126.9, 127.6, 127.8, 127.9, 128.2, 128.4, 128.6, 130.5, 132.5, 136.0, 137.4, 140.5, 166.6, 177.4. Anal. calcd for C₃₆H₄₂O₉: C, 69.88; H, 6.84. Found: C, 69.84; H, 6.76.



2'-Carboxybenzyl 3-O-benzyl-5,6-O-isopropylidene-2-O-pivaloyl-β-D-galactofuranoside (6).

Compound **17** (1.655 g, 2.67 mmol) was stirred under hydrogen atmosphere using a balloon in the presence of Pd/C (10%, 284 mg) and ammonium acetate (206 mg, 2.67 mmol) in MeOH–EtOAc (1:1 v/v, 10 mL) at room temperature for 1 h. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 1:1, v/v) to afford the title compound **6** (1.38 g, 2.61 mmol, 98%) as a colorless oil.: $R_f = 0.45$ (hexane/EtOAc, 1:1, v/v); IR (CHCl₃ film) 1694, 1732, 3172 cm⁻¹; $[\alpha]_D^{20} - 9.4$ (c 4, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.23 (s, 9 H), 1.35 (s, 3 H), 1.41 (s, 3 H), 3.75–3.85 (m, 3 H), 4.18–4.25 (m, 2 H), 4.58 and 4.84 (ABq, J = 11.9 Hz, 2 H), 5.08 and 5.25 (ABq, J = 15.1 Hz, 2 H), 5.24 (s, 1 H), 5.31 (s, 1 H), 7.25–7.35 (m, 6 H), 7.56 (t, J = 7.5 Hz, 1 H), 7.80 (d, J = 7.7 Hz, 1 H), 7.98 (d, J = 7.7 Hz, 1 H), 12.0 (brs, 1H); ¹³C NMR (63 MHz, CDCl₃) 25.3, 26.4, 27.0, 38.6, 65.4, 67.2, 72.0, 75.8, 80.5, 83.5, 83.7, 105.9, 109.8, 126.6, 126.9, 127.3, 127.9, 128.2, 128.3, 131.3, 133.3, 137.3, 141.3, 172.1, 166.4. Anal. calcd for C₂₉H₃₆O₉: C, 65.89; H, 6.86. Found: C, 65.86; H, 6.85.






2'-(Benzyloxycarbonyl)benzyl (2,3,5,6-tetra-O-benzyl- α -D-galactofuranosyl)-(1 \rightarrow 2) 3-O-benzyl-5,6-O-isopropylidene- β -D-galactofuranoside (19).

Method A: A solution of donor **5** (94 mg, 0.139 mmol), acceptor **16** (111 mg, 0.208 mmol) and DTBMP (86 mg, 0.419 mmol) in CH₂Cl₂ (10 mL) in the presence of 4Å molecular sieves was stirred for 10 min at room temperature and cooled to -78 °C. To the resulting solution was added a

solution of Tf₂O (35 μL, 0.208 mmol) in CH₂Cl₂ (1 mL), and stirred at -78 °C for 1 h. The reaction mixture was allowed to warm to 0 °C over 1 h, quenched with saturated aqueous NaHCO₃ (1 mL), and diluted with CH₂Cl₂(50 mL). The organic layer was washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound 19 (100 mg, 0.095 mmol, 68 %, α only) as a colorless oil and self-condensed ester 20 (20 mg, 0.033 mmol, 24%) as a colorless oil. Compound **19**: $R_f = 0.48$ (hexane/EtOAc, 3:1, v/v); ¹H NMR (250 MHz, CDCl₃) δ 1.33 (s, 3 H), 1.39 (s, 3 H), 3.60–3.64 (m, 2 H), 3.68–3.71 (m, 1 H), 3.75–3.79 (m, 2 H), 3.83-3.87 (m, 1 H), 3.97 (dd, J = 3.6, 7.6 Hz, 1 H), 4.04-4.09 (m, 2 H), 4.17 (t, J = 6.8 Hz, 1 H), 4.26 (d, J = 11.7 Hz, 1 H), 4.36-4.50 (m, 7 H), 4.57 (d, J = 3.7 Hz, 1 H), 4.61-4.64 (m, 1 H), 4.69 (brs, 1 H), 4.71 (d, J = 12.2 Hz, 1 H), 5.03 (d, J = 14.3 Hz, 1 H), 5.09 (d, J = 4.5 Hz, 1 H), 5.15(d, J = 13.4 Hz, 1 H), 5.18 (brs, 1 H), 5.31 (s, 2 H), 7.16 - 7.44 (m, 32 H), 7.66 (d, J = 7.7 Hz, 1 H),7.97 (d, J = 7.7 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 25.5, 26.7, 65.5, 66.7, 67.5, 70.7, 72.1, 72.4(2), 73.2, 73.5, 77.4, 79.6, 80.2,83.5,83.7, 84.6, 84.8, 99.0, 105.7, 109.7, 127.1,127.57, 127.6, 127.7, 127.77,127.8, 127.9, 128.0, 128.2, 128.25, 128.3, 128.36, 128.4, 128.5, 128.6,128.7, 130.6, 132.4, 136.1, 137.6, 138.1, 138.2, 138.5, 140.6, 166.7. Compound **20**: $R_f = 0.5$ (hexane/EtOAc, 3:1, v/v); ¹H NMR (500 MHz, CDCl₃) δ 3.63–3.69 (m, 4 H), 3.76–3.79 (m, 1 H), 3.80–3.84 (m, 1 H), 4.05-4.06 (m, 1 H), 4.09-4.15 (m, 3 H), 4.18-4.20 (m, 1 H), 4.31-4.34 (m, 2 H), 4.39-4.59 (m, 12 H), 4.66 (d, J = 11.9 Hz, 1 H), 4.70-4.75 (m, 2 H), 5.01 and 5.12 (ABq, J = 14.7 Hz, 2 H), 5.22 (brs, 1 H), 6.48 (brs, 1 H), 7.20–7.31 (m, 41 H), 7.48 (t, J = 7.3 Hz, 1 H), 7.67 (d, J = 7.6 Hz, 1 H), 7.95 (d, J = 7.6 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 67.5, 70.8, 71.2, 72.0, 72.2, 73.4, 73.5, 76.6, 81.4, 83.0, 84.9, 87.0, 88.6, 100.7, 106.1, 127.0, 127.7, 128.0, 128.5, 131.2, 132.9. Anal. calcd for

C₇₆H₇₆O₁₃: C, 76.23; H, 6.40. Found: C, 76.32; H, 6.32.

Method B: A solution of the acceptor 16 (116 mg, 0.217 mmol) and DTBMP (89 mg, 0.433 mmol) in CH₂Cl₂ (10 mL) in the presence of 4Å molecular sieves was stirred for 10 min at room temperature and cooled to -78 °C. To the resulting solution was added a solution of Tf₂O (37 μL, 0.220 mmol) in CH₂Cl₂ (1 mL) and subsequently added dropwise a solution of donor 5 (98 mg, 0.145 mmol) in CH₂Cl₂ (10 mL). After stirring at -78 °C for further 1 h, the reaction mixture was allowed to warm to 0 °C over 1 h, quenched with saturated aqueous NaHCO₃ (1 mL), and diluted with CH₂Cl₂ (50 mL). The organic layer was washed with saturated aqueous NaHCO₃ (2 × 50 mL) and brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography (hexanes/EtOAc, 3:1, v/v) to afford the title compound 19 (126 mg, 0.119 mmol, 82 %, α only).




2'-(Benzyloxycarbonyl)benzyl

 $(3-O-benzyl-5,6-O-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-\beta-D-isopropylidene-2-O-pivaloyl-β-D-isopropyl-β-D-isopropylidene-2-O-pivaloyl-β-D-isopropylidene-2-O-pivaloyl-β-D-isopropyl-β-D-is$


galactofuranosyl)-(1 \rightarrow 3)-2-*O*-benzyl-4,6-*O*-benzylidene-β-D-galactopyranoside (21). A solution of acceptor **7** (527 mg, 0.905 mmol) and DTBMP (667 mg, 3.248 mmol) in CH₂Cl₂ (15 mL) in the presence of 4Å molecular sieves was stirred for 10 min at room temperature and cooled to -45 °C. To the resulting solution was added a solution of Tf₂O (273 μL, 1.623 mmol) in CH₂Cl₂ (3 mL) and subsequently added dropwise a solution of donor **6** (715 mg, 1.353 mmol) in CH₂Cl₂ (10 mL). After stirring at -40 °C for further 1 h, the reaction mixture was allowed to warm to 0 °C over 1 h,

quenched with saturated aqueous NaHCO₃ (1 mL), and diluted with CH₂Cl₂ (50 mL) The organic layer was washed with saturated aqueous NaHCO₃ (2 × 50 mL) and brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 2:1, v/v) to afford the title compound **21** (682 mg, 0.711 mmol, 79%) as a white solid.: m.p.= 81–82 °C; R_f = 0.18 (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1258, 1374, 1459, 1717, 1736 cm⁻¹; $[\alpha]_D$ = 33.1 (c 1.1, CHCl₃); 1 H NMR (250 MHz, CDCl₃) δ 1.20 (s, 9 H), 1.34 (s, 6 H), 3.41 (brs, 1 H), 3.60 (d, J = 5.9 Hz, 1 H), 3.67 (d, J = 7.8 Hz, 1 H), 3.72–3.83 (m, 2 H), 3.93–4.15 (m, 3 H), 4.24–4.37 (m, 2 H), 4.41 (d, J = 3.4 Hz, 1 H), 4.47 and 4.79 (ABq, J = 12.0 Hz, 2 H), 4.55 (d, J = 7.7 Hz, 1 H), 4.83 and 4.91 (ABq, J = 10.7 Hz, 2 H), 5.14 and 5.41 (ABq, J = 15.1 Hz, 2 H), 5.27–5.33 (m, 4 H), 5.59 (s, 1 H), 7.23–7.59 (m, 22 H), 7.83 (d, J = 7.7 Hz, 1 H), 8.01 (d, J = 7.6 Hz, 1 H); 13 C NMR (63 MHz, CDCl₃) δ 25.5, 26.6, 27.1, 38.7, 65.5, 66.5, 66.7, 69.1, 72.0, 75.5, 76.4, 77.4, 76.5, 78.0, 79.4, 80.7, 83.5, 84.1, 100.8, 103.1, 108.5, 109.9, 126.3, 126.9, 127.4, 127.5, 127.6,128.0, 128.1, 128.2, 128.3, 128.4, 128.5, 128.7, 130.6, 132.7, 136.0, 137.3, 137.9,138.7, 140.9, 166.7, 177.1. Anal. calcd for C₅₆H₆₂O₁₄: C, 70.13; H, 6.52. Found: C, 70.04; H, 6.51.




2'-(Benzyloxycarbonyl)benzyl (3-O-benzyl-5,6-O-isopropylidene- β -D-galactofuranosyl)-(1 \rightarrow 3)-2-O-benzyl-4,6-O-benzylidene- β -D-galactopyranoside (4). A solution of benzyl alcohol (340 μ L, 3.29 mmol) and sodium hydride (60%, 132 mg, 3.30 mmol) in THF (10 mL) was stirred at

0 °C for 30 min. To the solution was added a solution of **21** (2.11 g, 2.20 mmol) in THF (4 mL) and stirred at 0 °C for 1 h. The reaction mixture was quenched with water (2 mL), diluted with EtOAc (50 mL), washed with brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography (hexane/EtOAc, 1:1, v/v) to afford the title compound **4** (1.58 g, 1.81 mmol, 82%) as a white solid.: m.p.= 47–48 °C; $R_f = 0.38$ (hexane/EtOAc, 1:1, v/v); IR (CHCl₃ film) 3442, 1717, 1463, 1378, 1262 cm⁻¹; [α]_D –26.2 (c 0.5, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.34 (s, 3 H), 1.37 (s, 3 H), 2.93 (brs, 1 H), 3.38 (brs, 1 H), 3.73–3.80 (m, 2 H), 3.83–3.98 (m, 3 H), 4.00–4.17 (m, 3 H), 4.19–4.24 (m, 1 H), 4.29–4.36 (m, 2 H), 4.47 and 4.65 (ABq, J = 11.9 Hz, 2 H), 4.55 (d, J = 7.7 Hz, 1 H), 4.73 and 4.92 (ABq, J = 11.2 Hz, 2 H), 5.11 and 5.40 (ABq, J = 14.9 Hz, 2 H), 5.27–5.29 (m, 3 H), 5.53 (s, 1 H), 7.16–7.55 (m, 22 H), 7.81 (d, J = 7.7 Hz, 1 H), 8.00 (dd, J = 1.0, 7.7 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 25.5, 26.1, 65.6, 66.6, 66.7, 69.1, 69.2, 71.9, 75.4, 76.5, 77.4, 78.4, 78.5, 79.2, 82.8, 86.3, 100.8, 103.1, 109.9, 111.1, 126.3, 126.9, 127.6, 127.7, 127.8, 128.0, 128.1, 128.27, 128.3, 128.4, 128.6, 132.6, 137.8, 138.0, 138.9, 140.8, 166.7. Anal. calcd for C₅₁H₅₄O₁₃: C, 70.01; H, 6.22. Found: C, 70.06; H, 6.30.



2'-(Benzyloxycarbonyl)benzyl (2,3,5,6-tetra-O-benzyl- α -D-galactofuranosyl)-(1 \rightarrow 2)-(3-O-benzyl-5,6-O-isopropylidene- β -D-galactofuranosyl)-(1 \rightarrow 3)-2-O-benzyl-4,6-O-benzylidene- β -D-galactopyranoside (22). A solution of acceptor 4 (93 mg, 0.106 mmol) and DTBMP (52 mg, 0.253

mmol) in CH₂Cl₂ (10 mL) in the presence of 4Å molecular sieves was stirred for 10 min at room temperature and cooled to -78 °C. To the resulting solution were added a solution of Tf₂O (22 μL, 0.131 mmol) in CH₂Cl₂ (1 mL) and subsequently added dropwise a solution of donor 5 (71 mg, 0.105 mmol) in CH₂Cl₂ (5 mL). After stirring at -78 °C for further 1 h, the reaction mixture was allowed to warm to 0 °C over 1 h, quenched with saturated aqueous NaHCO₃ (1 mL), and diluted with CH_2Cl_2 (50 mL). The organic layer was washed with saturated aqueous NaHCO₃ (2 × 50 mL) and brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography (hexane/EtOAc, 2:1, v/v) to afford the title compound 22 (134 mg, 0.096 mmol, 91%) as a white solid.: m.p.= 43-44 °C; $R_f = 0.3$ (hexane/EtOAc, 2:1, v/v); IR (CHCl₃ film) 1713, 1497, 1368, 1261 cm⁻¹; $[\alpha]_D$ +22.1 (c 0.8, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.34 (s, 6) H), 3.42 (brs, 1 H), 3.64–3.86 (m, 8 H), 3.91–4.02 (m, 2 H), 4.06–4.24 (m, 5 H), 4.31–4.41 (m, 8 H), 4.53-4.59 (m, 3 H), 4.64-4.70 (m, 2 H), 4.73 (d, J = 4.8 Hz, 1 H), 4.92 (d, J = 4.6 Hz, 1 H), 4.99 (d, J = 10.8 Hz, 1 H), 5.16 and 5.42 (ABq, J = 15.0 Hz, 2 H), 5.26 (brs, 1 H), 5.30 (s, 2 H),5.58 (s, 1 H), 7.20–7.55 (m, 42 H), 7.82 (d, J = 7.8 Hz, 1 H), 8.02 (dd, J = 1.1, 7.8 Hz, 1 H); 13 C NMR (63 MHz, CDCl₃) δ 25.5, 26.8, 65.4, 66.6, 66.7(2), 69.1, 70.7, 71.8, 72.1, 72.4, 73.2, 73.5,75.3, 76.5, 77.0, 77.4, 78.0, 79.2, 79.3, 80.0, 82.8, 83.8, 84.5, 85.0, 98.5, 100.9, 103.2, 108.4, 109.7, 126.3, 126.9, 127.4, 127.5, 127.6, 127.7, 127.8, 127.87, 127.9, 128.0, 128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 130.7, 132.6, 136.0, 137.6, 137.9, 138.1, 138.2, 138.3, 138.8, 140.8, 166.6. Anal. calcd for C₈₅H₈₈O₁₈: C, 73.05; H, 6.35. Found: C, 73.12; H, 6.22.



2'-Carboxybenzyl (2,3,5,6-tetra-O-benzyl- α -D-galactofuranosyl)-(1 \rightarrow 2)-(3-O-benzyl-5,6-O-isopropylidene- β -D-galactofuranosyl)-(1 \rightarrow 3)-2-O-benzyl-4,6-O-benzylidene- β -D-

galactopyranoside (2). Compound 22 (127 mg, 0.91 mmol) was stirred under hydrogen atmosphere using a balloon in the presence of Pd/C (10%, 10 mg) and ammonium acetate (7 mg, 0.091 mmol) in MeOH-EtOAc (1:1, v/v, 5 mL) at room temperature for 1 h. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography (hexane/EtOAc, 1:2, v/v) to afford the title compound 2 (112 mg, 0.086 mmol, 95%) as a white solid.: m.p.= 48-49 °C; $R_f = 0.3$ (hexane/EtOAc, 1:2, v/v); IR (CHCl₃) film) 3306, 1715, 1499, 1457, 1376 cm⁻¹; $[\alpha]_D$ +23.8 (c 1.0, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.34 (s, 6 H), 3.48 (brs, 1 H), 3.62–3.86 (m, 8 H), 3.94–4.02 (m, 3 H), 4.07–4.20 (m, 3 H), 4.21-4.24 (m, 1 H), 4.36-4.48 (m, 8 H), 4.54-4.72 (m, 5 H), 4.76 and 5.03 (ABq, J = 10.8 Hz, 2 H), 4.92 (d, J = 4.5 Hz, 1 H), 5.22 and 5.43 (ABq, J = 15.5 Hz, 2 H), 5.27 (brs, 1 H), 5.59 (s, 1 H), 7.20-7.56 (m, 37 H), 7.87 (d, J = 7.8 Hz, 1 H), 8.07 (d, J = 7.7 Hz, 1 H), 9.77 (brs, 1 H); 13 C NMR (63 MHz, CDCl₃) δ 25.6, 26.8, 65.4, 66.6, 69.1(2), 70.7, 71.9,72.2, 72.4, 73.3, 73.5(2), 75.4, 76.5, 77.0, 78.1, 79.3(2), 80.0, 82.8, 83.8, 84.5, 85.0, 98.5, 100.9,103.1, 108.4, 109.8, 126.3, 126.6, 127.0, 127.5, 127.6, 127.68, 127.7, 127.8, 127.9, 127.97, 128.0, 128.1, 128.27, 128.3, 128.36, 128.4, 128.5, 128.7, 131.5, 133.4, 137.7, 138.0, 138.15, 138.2, 138.4, 138.8, 141.5, 171.8. Anal. calcd for C₇₈H₈₂O₁₈: C, 71.65; H, 6.32. Found: C, 71.60; H, 6.45.

(2*R*,3*S*,4*R*)-1-*O*-*t*-Buthyldiphenylsilyl-3,4-*O*-isopropylidene-5-hexene-1,2,3,4-tetrol (24). To a suspension of trimethylphosphonium bromide (6.0 g, 16.8 mmol) in THF (50 mL) was added dropwise *n*-BuLi (1.6 M, 10.5 mL, 16.8 mmol) at 0 °C, and the mixture was stirred at 0 °C for 30 min. To this mixture was added dropwise a solution of **23** (2.3 g, 5.37 mmol) in THF (20 mL) at 0 °C, and allowed to warm to room temperature, then stirred for 1 h. After the reaction mixture was quenched with methanol, it was dissolved in 80% aqueous methanol and extracted with n-hexane (100 mL), washed with brine (2 × 50 mL) and then concentrated. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 4:1, v/v) to afford the title compound **24** (2.06 g, 4.83 mmol, 90%) as a colorless oil.: $R_f = 0.53$ (hexane/EtOAc, 4:1, v/v); IR (CHCl₃ film) 1111, 1429, 3467 cm⁻¹; $[\alpha]_D^{20} - 15.0$ (*c* 1.0, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.06 (s, 9 H), 1.39 (s, 3 H), 1.51 (s, 3 H), 2.43 (d, J = 6.2 Hz, 1 H), 3.63–3.72 (m, 3 H), 4.30 (dd, J = 3.6, 6.9 Hz, 1 H), 4.50 (t, J = 7.5 Hz, 1 H), 5.18 (brs, 1 H), 5.23 (dd, J = 0.8, 6.9 Hz, 1 H), 5.88–6.03 (m, 1 H), 7.34–7.68 (m, 10 H); ¹³C NMR (63 MHz, CDCl₃) δ 19.4, 25.1, 27.0, 27.4, 65.0, 70.1, 77.3, 79.2, 108.8, 119.5, 127.86, 127.9, 129.9, 130.0, 133.3, 134.5, 135.7. Anal. calcd for C₂₅H₃₄O₄Si: C, 70.38; H, 8.03. Found: C, 70.24; H, 8.38.

(2R,3S,4R)-1-O-t-Buthyldiphenylsilyl-3,4-O-isopropylidene-5-hexadecene-15-methyl-1,2,3,4-

tetrol (25). To a solution of 24 (320 mg, 0.75 mmol) and 11-methyl-dodec-1-ene (39) (1.37 g, 7.51 mmol) in CH₂Cl₂ (25 mL) was added the Grubbs generation II catalyst 41 (127 mg, 0.15 mmol). The reaction mixture was stirred at reflux for 24 h, concentrated and directly purified by silica gel flash column chromatography (hexane/EtOAc, 9:1, v/v) to afford the title compound 25 (327 mg, 0.56 mmol, 75%) as a colorless oil.: $R_f = 0.45$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1112, 3483 cm⁻¹; $[\alpha]_D^{20}$ –3.9 (c 0.9, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.86 (s, 3 H), 0.87 (s, 3 H), 1.07 (s, 9 H), 1.15–1.35 (m, 15 H), 1.38 (s, 3 H), 1.50 (s, 3 H), 2.00–2.02 (m, 2 H), 2.42 (d, J = 4.5 Hz, 1 H), 3.65–3.70 (m, 3 H), 4.26 (dd, J = 2.2, 6.2 Hz, 1 H), 4.51 (t, J = 7.3 Hz, 1 H), 5.58–5.70 (m, 2 H), 7.36–7.67 (m, 10 H); ¹³C NMR (125 MHz, CDCl₃) δ 19.4, 22.8, 25.0, 27.0, 27.3, 27.5, 28.1, 29.1, 29.3, 29.6, 29.7, 30.0, 32.3, 39.1, 65.0, 70.2, 77.2, 79.1, 108.3, 125.7, 127.8, 129.9, 133.3, 135.7, 137.4. Anal. calcd for C₃₆H₅₆O₄Si: C, 74.43; H, 9.72. Found: C, 74.69; H, 9.94.

(2R,3S,4R)-1-O-t-Buthyldiphenylsilyl-3,4-O-isopropylidene-5-heptadecene-16-methyl-1,2,3,4-

tetrol (**26**). The title compound **26** was prepared from compound **24** (180 mg, 0.42 mmol) in the same procedure as described for **25**: 190 mg (0.319 mmol, 76%); colorless oil; $R_f = 0.45$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1111, 3421 cm⁻¹; $[\alpha]_D^{20}$ –2.8 (c 0.9, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.85 (s, 3 H), 0.87 (s, 3 H), 1.06 (s, 9 H), 1.13–1.35 (m, 14 H), 1.38 (s, 3 H), 1.50 (s, 3 H), 1.53–1.61 (m, 3 H), 1.97–2.04 (m, 2 H), 2.42 (brs, 1 H), 3.62–3.71 (m, 3 H), 4.23–4.27 (m, 1 H), 4.50 (t, J = 7.3 Hz, 1 H), 5.54–5.73 (m, 2 H), 7.34–7.68 (m, 10 H); ¹³C NMR (63 MHz, CDCl₃) δ 19.4, 22.8, 25.1, 27.0, 27.4, 27.6, 28.1, 29.1, 29.4, 29.6, 29.8, 29.9, 30.1, 32.4,

39.2, 65.0, 70.2, 77.3, 79.1, 108.4, 125.7, 127.86, 127.9, 129.94, 133.4, 135.7, 137.5. Anal. calcd for C₃₇H₅₈O₄Si: C, 74.70; H, 9.83. Found: C, 74.33; H, 9.99.

(2R,3S,4R)-1-O-t-Buthyldiphenylsilyl-3,4-O-isopropylidene-15-methyl-1,2,3,4-

hexadecanetetrol (27). Compound 25 (236 mg, 0.406 mmol) was stirred under hydrogen atmosphere using a balloon in the presence of Pd(OH)₂ (20%, 150 mg) in EtOAc (10 mL) at room temperature for 1.5 h. The reaction mixture was filtered through Celite and the filtrate was concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 9:1, v/v) to afford the title compound 27 (225 mg, 0.386 mmol, 95%) as a colorless oil.: $R_f = 0.50$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1112, 3416 cm⁻¹; $[\alpha]_D^{20} -10.8$ (c 0.6, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.86 (s, 3 H), 0.87 (s, 3 H), 1.07 (s, 9 H), 1.15–1.36 (m, 18 H), 1.36 (s, 3 H), 1.47 (s, 3 H), 1.49–1.72 (m, 3 H), 2.35 (brs, 1 H), 3.66–3.71 (m, 3 H), 4.09–4.18 (m, 2 H), 7.36–7.67 (m, 10 H); ¹³C NMR (125 MHz, CDCl₃) δ 25.3, 27.0(m), 27.4, 27.5, 28.1, 29.8(m), 30.0, 30.1, 39.2, 65.4, 70.0, 76.6, 77.6, 107.8, 127.9, 129.9, 133.4, 135.7. Anal. calcd for $C_{36}H_{58}O_4Si$; C, 74.17; H, 10.03. Found: C, 74.12; H, 10.32.

(2R,3S,4R)-1-O-t-Buthyldiphenylsilyl-3,4-O-isopropylidene-16-methyl-1,2,3,4-

heptadecanetetrol (28). The title compound 28 was prepared from compound 26 (422 mg, 0.709

mmol) in the same procedure as described for **27**: 398 mg (0.667 mmol, 94%); colorless oil; $R_f = 0.35$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1111, 3421 cm⁻¹; $[\alpha]_D^{20} - 8.6$ (c 0.7, CHCl₃); 1 H NMR (500 MHz, CDCl₃) δ 0.86 (s, 3 H), 0.87 (s, 3 H), 1.07 (s, 9 H), 1.15–1.32 (m, 20 H), 1.36 (s, 3 H), 1.46 (s, 3 H),1.49–1.53 (m, 2 H), 1.71–1.78 (m, 1 H), 2.35 (brs, 1 H), 3.67–3.71 (m, 3 H), 4.09–4.14 (m, 1 H), 4.16–4.21 (m, 1 H), 7.36–7.68 (m, 10 H); 13 C NMR (125 MHz, CDCl₃) δ 19.4, 22.8, 25.3, 27.0, 27.4, 27.5, 28.1, 29.8, 30.0, 30.1, 39.2, 65.4, 70.0, 76.6, 77.6, 107.8, 127.9, 129.9, 133.4, 135.7. Anal. calcd for $C_{37}H_{60}O_4Si$: C, 74.44; H, 10.13. Found: C, 74.35; H, 10.34.

(2S,3S,4R)-2-Azide-1-O-t-buthyldiphenylsilyl-3,4-O-isopropylidene-15-methyl-1,3,4-

hexadecanetriol (29). To a stirred solution of 27 (1.04 g, 1.78 mmol) in CH_2Cl_2 (10 mL) at 0 °C, trifluoromethanesulfonic anhydride (450 μ L, 2.76 mmol) and 2,6-di-*tert*-butyl-4-methylpyridine (567 mg, 2.76 mmol) were added. The resulting solution was stirred at 0 °C for 12 h. The reaction mixture was diluted with CH_2Cl_2 (50 mL) and washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (30 mL), dried (Na₂SO₄), and concentrated in vacuo. The residue was purified by silica gel quick column chromatography (hexane/EtOAc = 15:1, v/v) to afford the triflate intermediate (R_f = 0.43, hexane/EtOAc, 15:1, v/v). A solution of the triflate intermediate and tetramethylguanidinium azide (1.41 g, 8.91 mmol) in DMF (15 mL) was stirred at 0 °C for 10 min. The reaction mixture was diluted with EtOAc (100 mL), washed with saturated aqueous NH₄Cl (2 × 50 mL) and brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc = 15:1, v/v) to afford the title compound

29 (952 mg, 1.57 mmol, 88%) as a colorless oil.: $R_f = 0.55$ (hexane/EtOAc, 15:1, v/v); IR (CHCl₃ film) 1111, 2101 cm⁻¹; $[\alpha]_D^{20}$ +18.3 (c 0.3, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.85 (s, 3 H), 0.88 (s, 3 H), 1.08 (s, 9 H), 1.14–1.40 (m, 22 H), 1.41–1.59 (m, 5 H), 3.39–3.46 (m, 1 H), 3.85 (dd, J = 7.0, 10.8 Hz, 1 H), 3.95 (dd, J = 5.5, 9.7 Hz, 1 H), 4.03 (dd, J = 2.6, 10.8 Hz, 1 H), 4.09–4.16 (m, 1 H), 7.36–7.75 (m, 10 H); ¹³C NMR (63 MHz, CDCl₃) δ 19.3, 22.8, 25.8, 26.6, 26.8, 27.6, 28.1, 28.3, 29.6, 29.7, 29.8, 29.9, 30.1, 39.2, 61.9, 65.4, 75.4, 78.0, 108.3, 127.8, 127.9, 129.88, 129.9, 133.0, 133.2, 135.76, 135.8. Anal. calcd for $C_{36}H_{57}N_3O_3Si$: C, 71.12; H, 9.45; N, 6.91. Found: C, 71.19; H, 9.72; N, 6.73.

(2S,3S,4R)-2-Azide-1-O-t-buthyldiphenylsilyl-3,4-O-isopropylidene-16-methyl-1,3,4-

heptadecanetriol (30). The title compound 30 was prepared from compound 28 (133 mg, 0.223 mmol) in the same procedure as described for 29: 122 mg (0.196 mmol, 88%); colorless oil; $R_f = 0.55$ (hexane/EtOAc, 15:1, v/v); IR (CHCl₃ film) 1116, 2100 cm⁻¹; $[\alpha]_D^{20} + 16.8$ (c 0.8, CHCl₃); 1 H NMR (500 MHz, CDCl₃) δ 0.86 (s, 3 H), 0.87 (s, 3 H), 1.08 (s, 9 H), 1.13–1.42 (m, 24 H), 1.49–1.55 (m, 5 H), 3.42 (t, J = 7.3 Hz, 1 H), 3.85 (dd, J = 7.0, 10.5 Hz, 1 H), 3.94 (dd, J = 5.5, 9.5 Hz, 1 H), 4.03 (dd, J = 2.5, 10.5 Hz, 1 H), 4.09–4.15 (m, 1 H), 7.37–7.73 (m, 10 H); 13 C NMR (125 MHz, CDCl₃) δ 19.3, 22.8, 25.8, 26.6, 26.8, 27.6, 28.1, 28.3, 29.6, 29.8, 30.1, 31.7, 31.9, 39.2, 61.9, 65.4, 75.4, 78.0, 108.3, 127.8, 127.9, 129.9, 133.1, 133.2, 135.77, 135.8. Anal. calcd for C_{37} H₅₉N₃O₃Si: C, 71.45; H, 9.56; N, 6.76. Found: C, 71.27; H, 9.77; N, 6.86.

(2*S*,3*S*,4*R*)-2-Azide-1-*O*-*t*-buthyldiphenylsilyl-15-methyl-1,3,4-hexadecanetriol (S8). A solution of **29** (870 mg, 1.43 mmol) and trifluoroacetic acid (1 mL) in H₂O (0.1 mL) and CH₂Cl₂ (9 mL) was stirred at room temperature for 30 min. The reaction mixture was quenched with saturated aqueous NaHCO₃ (10 mL), and extracted with CH₂Cl₂ (2 × 50 mL). The combined organic layer was washed with saturated aqueous NaHCO₃ (2 × 50 mL) and brine (50 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 4:1, v/v) to afford the title compound **S8** (756 mg, 1.33 mmol, 93%) as a colorless oil.: $R_f = 0.38$ (hexane/EtOAc, 4:1, v/v); IR (CHCl₃ film) 1122, 2100, 3385 cm⁻¹; $[\alpha]_D^{20} + 23.5$ (*c* 0.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.86 (s, 3 H), 0.87 (s, 3 H), 1.08 (s, 9 H), 1.16–1.54 (m, 21 H), 2.14 (brs, 1 H), 2.67 (brs, 1 H), 3.53–3.58 (m, 1 H), 3.63–3.69 (m, 2 H), 3.91 (dd, J = 6.0, 10.5 Hz, 1 H), 4.03 (dd, J = 3.5, 10.5 Hz, 1 H), 7.38–7.70 (m, 10 H); ¹³C NMR (125 MHz, CDCl₃) δ 19.2, 22.8, 25.8, 26.9, 27.5, 28.1, 29.7, 30.1, 31.9, 39.2, 63.6, 64.3, 72.5, 74.2, 128.0, 130.1, 132.6, 132.7, 135.7. Anal. calcd for C₃₃H₅₃N₃O₃Si: C, 69.80; H, 9.41; N, 7.40. Found: C, 69.86; H, 9.08; N, 7.68.

(2*S*,3*S*,4*R*)-2-Azide-1-*O-t*-buthyldiphenylsilyl-16-methyl-1,3,4-heptadecanetriol (S9). The title compound S9 was prepared from compound 30 (57 mg, 0.0916 mmol) in the same procedure as described for S8: 49 mg (0.0842 mmol, 92%); colorless oil; R_f = 0.38 (hexane/EtOAc, 4:1, v/v); IR (CHCl₃ film) 1122, 2100, 3396 cm⁻¹; $[\alpha]_D^{20}$ +17.8 (*c* 0.8, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ

0.86 (s, 3 H), 0.87 (s, 3 H), 1.08 (s, 9 H), 1.14–1.56 (23 H), 2.07 (brs, 1 H), 2.59 (brs, 1 H), 3.52–3.60 (m, 1 H), 3.64–3.73 (m, 2 H), 3.91 (dd, J = 5.5, 10.5 Hz, 1 H), 4.03 (dd, J = 3.5, 10.5 Hz, 1 H), 7.40–7.70 (m, 10 H); ¹³C NMR (125 MHz, CDCl₃) δ 19.2, 22.8, 25.8, 26.9, 27.6, 28.1, 29.7, 30.1, 31.9, 39.2, 63.4, 64.3, 72.5, 74.2, 128.0, 130.2, 132.5, 135.7. Anal. calcd for C₃₄H₅₅N₃O₃Si: C, 70.18; H, 9.53; N, 7.22. Found: C, 70.07; H, 9.72; N, 7.52.

(2S,3S,4R)-2-Azide-3,4-di-O-benzoyl-1-O-t-buthyldiphenylsilyl-15-methyl-1,3,4-

hexadecanetriol (31). To a solution of compound S8 (340 mg, 0.60 mmol) in CH₂Cl₂ (5mL) and pyridine (5 mL) were added benzoyl chloride (209 μL, 1.80 mmol) and 4-(dimethylamino) pyridine (22 mg, 0.18 mmol). After stirring at room temperature for 12 h, the reaction mixture was quenched with NH₄Cl (5 mL) and extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layer was washed with 2N HCl (2 × 30 mL) and brine (30 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 15:1, v/v) to afford the title compound 31 (418 mg, 0.54 mmol, 90%) as a colorless oil.: $R_f = 0.65$ (hexane/EtOAc, 4:1, v/v); IR (CHCl₃ film) 1116, 1265, 1731, 2106 cm⁻¹; $[\alpha]_D^{20}$ +6.6 (*c* 0.65, CHCl₃); 1 H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.87 (s, 3 H), 1.05 (s, 9 H), 1.14–1.53 (m, 19 H), 1.75–1.85 (m, 2 H), 3.82–3.91 (m, 2 H), 3.95–4.04 (m, 1 H), 5.51–5.57 (m, 2 H), 7.19–7.67 (m, 16 H), 7.86–7.94 (m, 4 H); 13 C NMR (63 MHz, CDCl₃) δ 19.1, 22.8, 25.5, 26.7, 27.5, 28.1, 29.45, 29.5, 29.6, 29.7, 29.8, 29.83, 30.0, 39.1, 63.2, 64.2, 72.3, 73.2, 127.8, 127.9, 128.5, 128.6, 129.5, 129.8, 129.86, 129.9, 132.5, 132.8, 133.1, 133.4, 135.6, 135.65, 165.1, 165.7. Anal. calcd for

C₄₇H₆₁N₃O₅Si: C, 72.74; H, 7.92; N, 5.41. Found: C, 72.70; H, 7.63; N, 5.68.

(2S,3S,4R)-2-Azide-3,4-di-O-benzoyl-1-O-t-buthyldiphenylsilyl-16-methyl-1,3,4-

heptadecanetriol (**32**). The title compound **32** was prepared from compound **S9** (38 mg, 0.065 mmol) in the same procedure as described for **31**: 46 mg (0.058 mmol, 89%); colorless oil; $R_f = 0.65$ (hexane/EtOAc, 4:1, v/v); IR (CHCl₃ film) 1116, 1265, 1731, 2105 cm⁻¹; $[\alpha]_D^{20} + 9.4$ (*c* 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.85 (s, 3 H), 0.86 (s, 3 H), 1.04 (s, 9 H), 1.14–1.42 (m, 20 H), 1.43–1.52 (m, 1 H), 1.77–1.83 (m, 2 H), 3.79–3.90 (m, 2 H), 3.93–4.02 (m, 1 H), 5.44–5.58 (m, 2 H), 7.21–7.65 (m, 16 H), 7.87 (d, J = 7.5 Hz, 2 H), 7.91 (d, J = 7.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 19.2, 22.8, 25.5, 26.8, 27.5, 28.1, 29.5, 29.7, 29.8, 30.1, 39.2, 63.3, 64.3, 72.4, 73.3, 127.9,128.5, 128.6, 129.9, 132.6, 132.9, 133.1, 133.4, 135.7, 165.2, 165.8. Anal. calcd for $C_{48}H_{63}N_3O_5Si$: C, 72.97; H, 8.04; N, 5.32. Found: C, 72.88; H, 8.24; N, 5.16.

(2S,3S,4R)-2-Amino-3,4-di-O-benzoyl-1-O-t-buthyldiphenylsilyl-15-methyl-1,3,4-

hexadecanetriol (33). Compound 31 (355 mg, 0.457 mmol) was stirred under hydrogen atmosphere using a balloon in the presence of Pd(OH)₂ (20%, 177 mg) in MeOH–EtOAc (1:1, v/v, 10 mL) at room temperature for 4 h. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo. The residue was purified by silica gel flash column

chromatography (hexane/EtOAc, 4:1, v/v) to afford the title compound **33** (319 mg, 0.425 mmol, 93%) as a colorless oil.: $R_f = 0.28$ (hexane/EtOAc, 4:1, v/v); IR (CHCl₃ film) 1116, 1275, 1726, 3375 cm⁻¹; $[\alpha]_D^{20}$ –22.8 (c 1.2, CHCl₃); 1 H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.87 (s, 3 H), 1.04 (s, 9 H), 1.15–1.55 (m, 19 H), 1.77–1.83 (m, 2 H), 2.09 (brs, 2 H), 3.24–3.31 (m, 1 H), 3.65 (dd, J = 6.6, 10.2 Hz, 1 H), 3.84 (dd, J = 3.1, 10.2 Hz, 1 H), 5.51 (dd, J = 3.5, 7.3 Hz, 1 H), 5.62–5.68 (m, 1 H), 7.15–7.65 (m, 16 H), 7.90–7.93 (m, 4 H); 13 C NMR (63 MHz, CDCl₃) δ 19.3, 22.8, 25.6, 26.9, 27.5, 28.0, 29.5, 29.6, 29.7, 29.75, 30.0, 39.1, 53.6, 65.7, 73.9, 74.8, 127.7, 127.8, 128.0, 128.37, 128.4, 129.7, 129.8, 130.0, 130.1, 130.2, 132.9, 133.0, 133.1, 133.3, 135.6, 135.63, 165.5, 166.0. Anal. calcd for $C_{47}H_{63}NO_5Si$: C, 75.26; H, 8.47; N, 1.87. Found: C, 75.28; H, 8.25; N, 1.74.

(2S,3S,4R)-2-Amino-3,4-di-O-benzoyl-1-O-t-buthyldiphenylsilyl-16-methyl-1,3,4-

heptadecanetriol (34). The title compound 34 was prepared from compound 32 (39 mg, 0.0494 mmol) in the same procedure as described for 33: 36 mg (0.0471 mmol, 95%); colorless oil; $R_f = 0.28$ (hexane/EtOAc, 4:1, v/v); IR (CHCl₃ film) 1111, 1270, 1726, 3370 cm⁻¹; [α]_D²⁰ –14.0 (c 0.3, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.87 (s, 3 H), 1.03 (s, 9 H), 1.14–1.55 (m, 21 H), 1.75–1.83 (m, 2 H), 1.97 (brs, 2 H), 3.22–3.29 (m, 1 H), 3.63 (dd, J = 6.9, 10.2 Hz, 1 H), 3.83 (dd, J = 3.2, 10.2 Hz, 1 H), 5.48 (dd, J = 3.5, 7.4 Hz, 1 H), 5.59–5.65 (m, 1 H), 7.18–7.65 (m, 16 H), 7.88–7.92 (m, 4 H); ¹³C NMR (63 MHz, CDCl₃) δ 19.3, 22.8, 25.7,27.0, 27.5, 28.1, 29.6, 29.67, 29.7, 29.8, 30.1, 39.2, 53.6, 65.8, 74.0,74.9, 127.8, 127.9, 128.4, 128.5, 129.8, 129.84, 130.0,

130.1, 130.3, 133.0, 133.1, 133.3, 135.65, 135.7, 165.6, 166.1. HRMS (FAB) calcd for $C_{48}H_{65}NO_{5}SiNa\left(M+Na\right)^{+}:m/z$ 786.4530. Found: 786.4538.

(2S,3S,4R)-N-[(R)-2-Acetoxypentacosanoyl]-2-amino-3,4-di-O-benzoyl-1-O-t-

buthyldiphenylsilyl-15-methyl-1,3,4-hexadecanetriol (37). A solution of 33 (45 mg, 0.06 mmol), 35 (32 mg, 0.073 mmol), and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) (23 mg, 0.093 mmol) in CH₂Cl₂ (5 mL) was stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc (50 mL), washed consecutively with aqueous NaHCO₃, aqueous 1 N HCl. The organic layer was dried over MgSO₄, concentrated in vacuo, and the residue was purified by silica gel flash column chromatography (hexane/EtOAc, 9:1, v/v) to afford the title compound 37 (68 mg, 0.058 mmol, 97%) as a colorless oil.: $R_f = 0.33$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1112, 1280, 1690, 1731 cm⁻¹; [α]_D²⁰ +34.1 (*c* 0.8, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.86 (s, 3 H), 0.88 (t, J = 6.2 Hz, 3 H), 0.99 (s, 9 H), 1.07–1.53 (m, 61 H), 1.82–1.96 (m, 4 H), 2.04 (s, 3 H), 3.65 (dd, J = 2.9, 10.6 Hz, 1 H), 3.75 (dd, J = 2.6, 10.6 Hz, 1 H), 4.47–4.55 (m, 1 H), 5.31–5.37 (m, 2 H), 5.86 (dd, J = 2.3, 9.3 Hz, 1 H), 6.99–7.64 (m, 17 H), 7.95–8.00 (m, 4 H); ¹³C NMR (63 MHz, CDCl₃) δ 14.3, 19.3, 21.0, 22.8, 22.83, 25.0, 25.9, 26.7, 26.8, 27.6, 28.1, 28.6, 29.5, 29.6, 29.7, 29.8, 29.9, 30.1, 32.1, 32.4, 39.2, 49.7, 62.2, 72.0, 74.2, 74.3, 127.7, 127.8, 128.0, 128.5, 128.6, 129.9, 129.93, 130.0, 130.4, 132.1, 133.0, 133.3, 134.9, 135.4, 135.6, 165.2, 166.5, 169.7, 169.8. Anal. calcd for C_{74} H₁₁₃NO₈Si: C, 75.79; H, 9.71; N, 1.19. Found: C, 75.74; H, 9.55; N, 1.11.

(2S,3S,4R)-N-[(R)-2-Acetoxypentacosanoyl]-2-amino-3,4-di-O-benzoyl-15-methyl-1,3,4-

hexadecanetriol (3a). A solution of compound 37 (68 mg, 0.058 mmol) and Bu₄NF (1.0 M, 87 μL, 0.087 mmol) in THF (3 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 2:1, v/v) to afford the title compound 3a (52 mg, 0.056 mmol, 97 %) as a colorless oil.: $R_f = 0.38$ (hexane/EtOAc, 2:1, v/v); IR (CHCl₃ film) 1285, 1724, 3361 cm⁻¹; $[\alpha]_D^{20} + 58.3$ (c 0.4, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.87 (s, 3 H), 0.90 (t, J = 6.3 Hz, 3 H), 1.04–1.53 (m, 61 H), 1.87–1.89 (m, 2 H), 1.95–2.05 (m, 2 H), 2.18 (s, 3 H), 3.24 (brs, 1 H), 3.45–3.72 (m, 2 H), 4.36–4.43 (m, 1 H), 5.18 (t, J = 6.2 Hz, 1 H), 5.36–5.41 (m, 1 H), 5.54 (dd, J = 2.3, 9.4 Hz, 1 H), 7.18 (d, J = 9.4 Hz, 1 H), 7.32–7.62 (m, 6 H), 7.93–8.05 (m, 4 H); ¹³C NMR (63 MHz, CDCl₃) δ 14.2, 20.9, 22.7, 22.74, 25.0, 25.9, 27.5, 28.0, 28.5, 29.4, 29.5, 29.67, 29.7, 29.8, 30.0, 32.0, 39.1, 50.0, 61.2, 73.2, 74.0, 74.4, 128.4, 128.6, 129.2, 129.7, 129.9, 129.95, 133.1, 133.7, 166.3, 166.7, 170.2, 170.4. HRMS (FAB) calcd for C₅₈H₉₅NO₈Na (M+Na)⁺: m/z 956.6955. Found: 956.6971. Anal. calcd for C₅₈H₉₅NO₈: C, 74.55; H, 10.25; N, 1.50. Found: C, 74.44; H, 10.45; N, 1.37.


(2S,3S,4R)-N-[(R)-2-Acetoxypentacosanoyl]-2-amino-3,4-di-O-benzoyl-1-O-t-

buthyldiphenylsilyl-16-methyl-1,3,4-heptadecanetriol (38). The title compound 38 was prepared from compound 34 (33 mg, 0.043 mmol) and compound 36 (22 mg, 0.052 mmol) in the same procedure as described for 37: 48 mg (0.041 mmol, 95%); colorless oil; $R_f = 0.33$ (hexane/EtOAc, 9:1, v/v); IR (CHCl₃ film) 1112, 1286, 1690, 1731 cm⁻¹; $[\alpha]_D^{20}$ +38 (c 0.45, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.86 (s, 3 H), 0.88 (t, J = 6.2 Hz, 3 H), 0.99 (s, 9 H), 1.08–1.53 (m, 61 H), 1.81–1.96 (m, 4 H), 2.04 (s, 3 H), 3.66 (dd, J = 2.4, 10.4 Hz, 1 H), 3.73–3.76 (m, 1 H), 4.51 (t, J = 8.6 Hz, 1 H), 5.29–5.36 (m, 2 H), 5.85 (dd, J = 2.3, 8.6 Hz, 1 H), 7.00–7.60 (m, 17 H), 7.91–8.05 (m, 4 H); ¹³C NMR (125 MHz, CDCl₃) δ 14.3, 19.2, 21.0, 22.8, 25.0, 25.9, 26.8, 27.6, 28.1, 28.6, 29.5, 29.6, 29.8, 30.1, 32.1, 32.4, 39.2, 49.7, 62.3, 72.0, 74.2, 74.3, 127.7, 128.0, 128.4, 128.6, 129.9, 130.4, 132.2, 132.8, 133.0, 133.3, 135.4, 135.6, 165.2, 166.5, 169.7, 169.8. Anal. Calcd for C₇₄H₁₁₃NO₈Si: C, 75.79; H, 9.71; N, 1.19. Found: C, 75.81; H, 9.35; N, 1.08.

(2S,3S,4R)-N-[(R)-2-Acetoxypentacosanoyl]-2-amino-3,4-di-O-benzoyl-16-methyl-1,3,4-

heptadecanetriol (3b). The title compound 3b was prepared from compound 38 (48 mg, 0.0409 mmol) in the same procedure as described above 3a: 37 mg (0.0396 mmol, 97%); colorless oil; $R_f = 0.38$ (hexane/EtOAc, 2:1, v/v); IR (CHCl₃ film) 1278, 1670, 1732, 3357 cm⁻¹; [α]_D²⁰ +54.2 (c 0.3, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.87 (s, 3 H), 0.88 (t, J = 6.2 Hz, 3 H), 1.12–1.56 (m, 61 H), 1.87–1.89 (m, 2 H), 0.98–2.05 (m, 2 H), 2.21 (s, 3 H), 2.76 (brs, 1 H), 3.49–3.71 (m, 2 H), 4.32–4.39 (m, 1 H), 5.19 (t, J = 6.1 Hz, 1 H), 5.36–5.40 (m, 1 H), 5.45 (dd, J = 2.4, 9.3 Hz, 1 H), 7.03 (d, J = 9.3 Hz, 1 H), 7.35–7.67 (m, 6 H), 7.94–8.07 (m, 4 H); ¹³C NMR (63


MHz, CDCl₃) δ 14.3, 21.2, 22.8, 22.83, 25.1, 26.0, 27.6, 28.1, 28.6, 29.45, 29.5, 29.54, 29.6, 29.75, 29.8, 29.85, 30.1, 32.1, 39.2, 50.0, 61.4, 73.6, 73.9, 74.4, 128.5, 128.8, 129.1, 129.8, 130.0, 130.1, 133.3, 134.0, 166.3, 167.2, 170.2, 170.4. MALDI-TOF calcd for C₅₈H₉₅NO₈Na (M+Na)⁺: *m/z* 956.6955. Found: 956.7050. Anal. calcd for C₅₈H₉₅NO₈: C, 74.55; H, 10.25; N, 1.50. Found: C, 74.53; H, 10.30; N, 1.44.




2,3,5,6-Tetra-*O*-benzyl-α-D-galactofuranosyl-(1 \rightarrow 2)-(3-*O*-benzyl-5,6-*O*-isopropylidene-β-D-galactofuranosyl)-(1 \rightarrow 3)-2-*O*-benzyl-4,6-*O*-benzylidene-D-galactopyranosyl fluoride (43). A solution of donor 2 (100 mg, 0.077 mmol) and DTBMP (50 mg, 0.24 mmol) in CH₂Cl₂ (10 mL) in the presence of 4Å molecular sieves was stirred for 10 min at room temperature and cooled to -78 °C. To the resulting solution was added a solution of Tf₂O (20 μL, 0.12 mmol) and subsequently added hydrogen fluoride (70% in pyridine, 6 μL, 0.23 mmol), then the solution was stirred at -78 °C for further 1 h and allowed to warm to 0 °C over 1 h. The reaction mixture was quenched with saturated aqueous NaHCO₃ (1 mL) and diluted with CH₂Cl₂ (50 mL). The organic layer was washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (50 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography (hexane/EtOAc, 2:1, v/v) to afford the title compound 43 (75 mg, 0.064 mmol, 83 %, β/α = 20:1). 43α: colorless oil, $R_f = 0.4$ (hexane/EtOAc, 2:1, v/v); IR (CHCl₃ film) 2925, 1456, 1125 cm⁻¹; [α]_D +52.0 (*c* 0.1,

CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.32 (s, 3 H), 1.33 (s, 3 H), 3.62–3.79 (m, 6 H), 3.88–4.01 (m, 4 H), 4.06–4.26 (m, 6 H), 4.31–4.44 (m, 7 H), 4.48–4.58 (m, 3 H), 4.63–4.73 (m, 4 H), 4.96 (d, J = 4.6 Hz, 1 H), 5.26 (brs, 1 H), 5.56 (s, 1 H), 5.63 and 5.85 (dd, J = 2.3, 53.4 Hz, 1 H), 7.21–7.50 (m, 35 H); ¹³C NMR (63 MHz, CDCl₃) δ 25.6, 26.8, 64.9, 65.5, 69.0, 70.8, 72.0, 72.5(2), 73.3, 73.5, 73.8, 74.2 and 74.6 (d, J = 23.9 Hz, C-2), 75.6, 76.3, 77.0, 77.4, 79.4, 80.1, 83.0, 83.9, 84.8, 84.9, 98.8, 100.7, 104.9 and 108.5 (d, J = 223.5 Hz, C-1), 108.5, 109.8, 126.2, 127.6, 127.7, 127.8, 127.9, 128.0, 128.06, 128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 128.63, 128.9, 137.67, 138.0, 138.16, 138.2, 138.3, 138.4. HRMS (FAB) calcd for (M+Na)⁺: m/z 1197.4988. Found: 1197.4991. Anal. calcd for $C_{70}H_{75}FO_{15}$: C, 71.53; H, 6.43. Found: C, 71.61; H, 6.26.

43p: colorless oil, $R_f = 0.25$ (nexane/EtOAc, 2:1, v/v); IR (CHCl₃ film) 2929, 1459, 1102 cm⁻¹; [α]_D +68.0 (c 0.2, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 1.34 (s, 6 H), 3,51 (brs, 1 H), 3.60–3.78 (m, 7 H), 3.83–3.88 (m, 1 H), 3.96–3.97 (m, 1 H), 3.99–4.01 (m, 1 H), 4.07–4.20 (m, 4 H), 4.23 and 4.55 (ABq, J = 11.4 Hz, 2 H), 4.31–4.43 (m, 8 H), 4.52 (d, J = 2.0 Hz, 1 H), 4.61–4.72 (m, 3 H), 4.86 (d, J = 10.9 Hz, 1 H), 4.90 (d, J = 4.7 Hz, 1 H), 5.12 and 5.34 (dd, J = 7.2, 53.0 Hz, 1 H), 5.23 (brs, 1 H), 5.56 (s, 1 H), 7.15–7.53 (m, 35 H); ¹³C NMR (63 MHz, CDCl₃) δ 25.5, 26.8, 65.4, 66.8, 66.9, 68.7, 70.7, 71.9, 72.2, 72.4, 73.3, 73.5, 75.2, 75.7, 77.0, 77.4 and 77.8 (d, J = 30.3 Hz, C-2), 77.9, 79.3, 80.1, 83.2, 83.9, 84.4, 84.9, 98.6, 101.0, 108.3, 108.7 and 112.1 (d, J = 215.5 Hz, C-1), 109.8, 126.3, 127.5, 127.6, 127.7, 127.75, 127.8, 127.9, 127.97, 128.0, 128.2, 128.3, 128.4, 128.44, 128.5, 128.9, 137.7, 138.1, 138.16, 138.2, 138.3, 138.4. HRMS (FAB) calcd for (M+Na)⁺: m/z 1197.4988. Found: 1197.4987. Anal. calcd for $C_{70}H_{75}FO_{15}$: C, 71.53; H, 6.43. Found: C, 71.28; H, 6.54.





Synthesis of 42a (Glycosylation of ceramide 3a).

Method A: Using CB glycoside 2 as glycosyl donor.

A solution of ceramide **3a** (150 mg, 0.161 mmol) and 2,6-di-*tert*-butyl-4-methylpyridine (83 mg, 0.404 mmol) in CH₂Cl₂ (20 mL) in the presence of 4Å molecular sieves was stirred for 10 min at room temperature and cooled to -78 °C. To the resulting solution were added sequentially a solution of Tf₂O (34 µL, 0.202 mmol) and dropwise a solution of CB glycosyl donor **2** (175 mg, 0.134 mmol) in CH₂Cl₂ (10 mL). The reaction mixture was stirred for further 1 h at -78 °C, allowed to warm over 1 h to 0 °C, diluted with CH₂Cl₂ (50 mL), and quenched with saturated aqueous NaHCO₃ (2 mL). The organic layer was washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (30 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound **42a** (216 mg, 0.103 mmol, 77%, $\alpha/\beta = 1.4:1$).

Method B: Using glycosyl fluoride 43 as glycosyl donor.

A solution of ceramide 3a (27 mg, 0.029 mmol), tin(II) chloride (13 mg, 0.069 mmol), silver perchlorate (14 mg, 0.068 mmol), and 2,6-di-*tert*-butyl-4-methylpyridine (7 mg, 0.034 mmol) in THF (5 mL) in the presence of 4 Å molecular sieves was stirred for 30 min at room temperature and cooled to -10 °C. To the resulting solution was dropwise added a solution of glycosyl fluoride 43 (52 mg, 0.044 mmol) in THF (2 mL) at -10 °C. The reaction mixture was stirred for further 1 h at -

10 °C, allowed to warm over 1 h to room temperature, diluted with diethyl ether (50 mL), and quenched with saturated aqueous NaHCO₃ (5 mL). The organic layer was washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (30 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound $42a\alpha$ (43 mg, 0.021 mmol, 72%).

42aα : colorless oil, $R_f = 0.35$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1262, 1367, 1525, 1679, 1728, 3321 cm⁻¹; $[α]_D^{20} + 47.6$ (c 2.0, CHCl₃); 1 H NMR (500 MHz, CDCl₃) δ 0.85 (s, 3 H), 0.86 (s, 3 H), 0.88 (t, J = 6.5 Hz, 3 H), 1.14–1.51 (m, 67 H), 1.82–1.95 (m, 4 H), 2.15 (s, 3 H), 3.56–3.68 (m, 5 H), 3.72–3.78 (m, 2 H), 3.90–4.04 (m, 6 H), 4.09–4.15 (m, 3 H), 4.22 (d, J = 12.0 Hz, 1 H), 4.30 (d, J = 11.5 Hz, 1 H), 4.37–4.48 (m, 7 H), 4.50–4.60 (m, 6 H), 4.63–4.69 (m, 2 H), 4.78 (d, J = 3.1 Hz, 1 H), 5.01 (d, J = 4.0 Hz, 1 H), 5.13 (t, J = 5.8 Hz, 1 H), 5.17–5.27 (m, 1 H), 5.21 (brs, 1 H), 5.57 (s, 1 H), 5.70 (d, J = 9.5 Hz, 1 H), 7.14–7.55 (m, 41 H), 7.68 (d, J = 10.0 Hz, 1 H), 7.93 (d, J = 7.5 Hz, 2 H), 7.99 (d, J = 7.5 Hz, 2 H); 13 C NMR (125 MHz, CDCl₃) δ 14.2, 21.1, 22.8, 25.3, 25.6, 25.9, 26.7, 27.5, 27.8, 28.1, 29.5, 29.8(m), 30.0, 32.0, 32.3, 39.2, 48.7, 63.8, 65.5, 69.3, 70.8, 71.3, 71.9, 72.3,72.4, 73.3, 73.5, 73.7, 74.2, 74.5, 74.9, 75.9, 76.69, 76.7, 77.3, 79.6, 80.1, 82.5, 83.7, 84.6, 84.8, 98.5, 100.5, 100.8, 107.9, 109.6, 126.1, 127.4, 127.6, 127.7, 127.9, 128.1, 128.25, 128.3, 128.4, 128.6, 129.8, 129.9, 130.2, 133.1, 133.4, 137.7, 138.2, 138.4, 165.1, 166.6, 170.5, 171.1. MALDI-TOF calcd for C₁₂₈H₁₆₉NNaO₂₃ (M+Na)⁺: m/z 2111.1983. Found: 2111.1982. Anal. calcd for C₁₂₈H₁₆₉NO₂₃: C, 73.57; H, 8.15; N, 0.67. Found: C, 73.57; H, 8.35; N, 0.62.

42aβ : colorless oil, $R_f = 0.18$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1285, 1455, 1690, 1721, 3388 cm⁻¹; $[\alpha]_D^{20}$ +48.6 (*c* 0.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.86 (s, 3 H), 0.88 (t, J = 6.0 Hz, 3 H), 1.13–1.51 (m, 67 H), 1.76–2.01 (m, 4 H), 1.85 (s, 3 H), 3.45 (brs, 1 H),

3.56–3.73 (m, 8 H), 3.82–3.91 (m, 2 H), 3.92–4.01 (m, 3 H), 4.05–4.14 (m, 2 H), 4.19 (d, J = 12.0 Hz, 1 H), 4.26 (d, J = 11.5 Hz, 1 H), 4.28–4.32 (m, 1 H), 4.33–4.44 (m, 8 H), 4.49 (brs, 1 H), 4.55–4.59 (m, 3 H), 4.65 (d, J = 12.5 Hz, 1 H), 4.68 (d, J = 11.5 Hz, 1 H), 4.77 (d, J = 11.0 Hz, 1 H), 4.92 (d, J = 4.0 Hz, 1 H), 5.10 (t, J = 6.1 Hz, 1 H), 5.19 (brs, 1 H), 5.35–5.39 (m, 1 H), 5.54 (s, 1 H), 5.75 (dd, J = 3.1, 8.6 Hz, 1 H), 6.93 (d, J = 9.0 Hz, 1 H), 7.15–7.54 (m, 41 H), 7.95 (d, J = 7.5 Hz, 2 H), 8.01 (d, J = 7.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 14.2, 20.9, 22.8, 25.0, 25.6, 25.7, 26.8, 27.5, 28.1, 28.7, 29.5, 29.8(m), 30.0, 32.0, 39.2, 48.3, 65.5, 66.7, 68.1, 69.0,70.8, 71.9, 72.2, 72.4, 73.0, 73.3, 73.6, 73.9, 74.2, 75.4, 76.3, 76.9, 77.9, 79.2, 79.4, 80.1, 83.0, 83.8, 84.5, 85.1, 98.7, 100.5, 104.4, 108.4, 109.8, 126.1, 127.7, 128.0, 128.1, 128.4, 129.8, 130.0, 130.1, 133.1, 133.4, 137.7, 138.1, 138.2, 138.4, 138.7, 165.5, 166.2, 170.3, 170.5. MALDI-TOF calcd for C₁₂₈H₁₆₉NNaO₂₃ (M+Na)⁺: m/z 2111.1983. Found: 2111.1980. Anal. calcd for C₁₂₈H₁₆₉NO₂₃: C, 73.57; H, 8.15; N, 0.67. Found: C, 73.65; H, 8.38; N, 0.63.

Synthesis of 42b (Glycosylation of ceramide 3b).

Method A: Using CB glycoside 2 as glycosyl donor.

A solution of ceramide **3b** (170 mg, 0.182 mmol) and 2,6-di-*tert*-butyl-4-methylpyridine (93 mg, 0.453 mmol) in CH_2Cl_2 (20 mL) in the presence of 4Å molecular sieves was stirred for 10 min at room temperature and cooled to -78 °C. To the resulting solution were added sequentially a solution

of Tf₂O (38 μ L, 0.226 mmol) and dropwise a solution of CB glycosyl donor **2** (197 mg, 0.151 mmol) in CH₂Cl₂ (10 mL). The reaction mixture was stirred for further 1 h at -78 °C, allowed to warm over 1 h to 0 °C, diluted with CH₂Cl₂ (50 mL), and quenched with saturated aqueous NaHCO₃ (2 mL). The organic phase was washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (30 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 3:1, v/v) to afford the title compound **42b** (237 mg, 0.113 mmol, 75%, $\alpha/\beta = 1.4:1$).

Method B: Using glycosyl fluoride 43 as glycosyl donor.


A solution of ceramide **3b** (25 mg, 0.027 mmol), tin(II) chloride (12 mg, 0.063 mmol), silver perchlorate (13 mg, 0.063 mmol), and 2,6-di-*tert*-butyl-4-methylpyridine (7 mg, 0.034 mmol) in THF (5 mL) in the presence of 4Å molecular sieves was stirred for 30 min at room temperature and cooled to -10 °C. To the resulting solution was dropwise added a solution of glycosyl fluoride **43** (47 mg, 0.040 mmol) in THF (2 mL) at -10 °C. The reaction mixture was stirred for further 1 h at -10 °C, allowed to warm over 1 h to room temperature, diluted with diethyl ether (50 mL), and quenched with saturated aqueous NaHCO₃ (5 mL). The organic phase was washed with saturated aqueous NaHCO₃ (2 × 30 mL) and brine (30 mL), dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane /EtOAc, 3:1, v/v) to afford the title compound **42ba** (41 mg, 0.020 mmol, 74%).

42bα : colorless oil, $R_f = 0.35$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1267, 1456, 1679, 1729, 3330 cm⁻¹; $[\alpha]_D^{20}$ +47.4 (*c* 0.2, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.87 (s, 3 H), 0.88 (t, J = 6.3 Hz, 3 H), 1.35–1.55 (m, 67 H), 1.81–1.85 (m, 4 H), 2.15 (s, 3 H), 3.55–3.76 (m, 7 H), 3.88–4.01 (m, 5 H), 4.03–4.19 (m, 4 H), 4.25 (d, J = 6.8 Hz, 1 H), 4.29–4.45 (m, 8 H),

4.51–4.53 (m, 3 H), 4.57–4.66 (m, 4 H), 4.68 (d, J = 7.7 Hz, 1 H), 4.80 (d, J = 3.2 Hz, 1 H), 5.01 (d, J = 4.6 Hz, 1 H), 5.10 (d, J = 6.0 Hz, 1 H), 5.18–5.27 (m, 2 H), 5.56 (s, 1 H), 5.74 (dd, J = 1.9, 10.2 Hz, 1 H), 7.12–7.60 (m, 41 H), 7.83 (d, J = 9.8 Hz, 1 H), 7.90–8.01 (m, 4 H); ¹³C NMR (63 MHz, CDCl₃) δ 14.3, 21.1, 22.8, 25.3, 25.6, 25.9, 26.7, 27.6, 27.8, 28.1, 29.5, 29.54, 29.6, 29.78, 29.8(m), 30.1, 32.0, 32.3, 39.2, 48.7, 63.7, 65.5, 69.3, 70.3, 70.8, 71.2, 71.9, 72.2, 72.4, 73.3, 73.5, 73.7, 74.2, 74.5, 75.0, 75.8,77.4, 79.5, 80.1, 82.5, 83.7, 84.5, 84.8, 98.4, 100.4, 100.6, 108.0, 109.7, 126.1, 127.6, 127.7, 128.0, 128.1, 128.2, 128.28, 128.3, 128.36, 128.4, 128.43, 128.5, 129.8, 130.1, 133.1, 133.5, 137.7, 138.1, 138.2, 138.25, 138.26, 138.4, 165.1, 166.6, 170.6, 171.1 MALDI-TOF calcd for C₁₂₈H₁₆₉NNaO₂₃ (M+Na)⁺: m/z 2111.1983. Found: 2111.1982. Anal. calcd for C₁₂₈H₁₆₉NO₂₃: C, 73.57; H, 8.15; N, 0.67. Found: C, 73.69; H, 8.30; N, 0.62.

42bβ : colorless oil, $R_f = 0.18$ (hexane/EtOAc, 3:1, v/v); IR (CHCl₃ film) 1281, 1686, 1728, 3388 cm⁻¹; $[\alpha]_D^{20} + 48.4$ (c 0.1, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.86 (s, 3 H), 0.88 (t, J = 6.3 Hz, 3 H), 1.13–1.55 (m, 67 H), 1.65–2.04 (m, 4 H), 1.86 (s, 3 H), 3.45 (brs, 1 H), 3.59–3.71 (m, 8 H), 3.84–3.99 (m, 5 H), 4.05–4.13 (m, 2 H), 4.17 (d, J = 12.0 Hz, 1 H), 4.25 (d, J = 11.5, Hz, 1 H), 4.29–4.43 (m, 9 H), 4.50 (d, J = 1.7 Hz, 1 H), 4.54–4.66 (m, 4 H), 4.68 (d, J = 11.6 Hz, 1 H), 4.78 (d, J = 10.9 Hz, 1 H), 4.92 (d, J = 4.6 Hz, 1 H), 5.09 (t, J = 6.1 Hz, 1 H), 5.19 (brs, 1 H), 5.34–5.38 (m, 1 H), 5.53 (s, 1 H), 5.76 (dd, J = 3.3, 8.6 Hz, 1 H), 7.02 (d, J = 9.2 Hz, 1 H), 7.12–7.56 (m, 41 H), 7.93–8.02 (m, 4 H); ¹³C NMR (63 MHz, CDCl₃) δ 13.8, 21.0,22.8, 24.4, 25.1, 25.6, 25.8, 26.8, 27.6, 28.1, 28.6, 29.5, 29.6, 29.7, 29.79, 29.8(m), 30.1, 32.1, 39.2, 40.6, 45.9, 48.3, 65.5, 66.6, 68.2, 69.0,70.8, 71.9, 72.2, 72.5, 72.9, 73.3, 73.6, 73.9, 74.2, 75.5, 76.3, 76.9, 77.0, 77.9, 79.1, 79.4, 80.1, 81.9, 83.0, 83.8, 84.4, 85.1, 98.6, 100.5, 104.5, 108.4, 109.8, 126.1, 127.6, 127.7, 127.8, 128.0, 128.03, 128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 129.8, 133.1, 133.5, 137.6, 138.0,

138.2, 138.21, 138.4, 138.7, 165.5, 166.3, 170.4, 170.5. MALDI-TOF calcd for C₁₂₈H₁₆₉NNaO₂₃ (M+Na)⁺: *m/z* 2111.1983. Found: 2111.1982. Anal. calcd for C₁₂₈H₁₆₉NO₂₃: C, 73.57; H, 8.15; N, 0.67. Found: C, 73.62; H, 8.42; N, 0.67.




Compound S10. To a solution of **42a**α (110 mg, 0.0526 mmol) in CH₂Cl₂ (8 mL) was added trifluoroacetic acid (2 mL). The resulting solution was stirred at room temperature for 30 min. The reaction mixture was diluted with CH₂Cl₂ (50 mL), washed with saturated aqueous NaHCO₃ (2 × 50 mL) and brine (50 mL), dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (hexane/EtOAc, 1:2, v/v) to afford the title compound **S10** (92 mg, 0.0469 mmol, 89%) as a colorless oil.: $R_f = 0.2$ (hexane/EtOAc, 1:2, v/v); IR (CHCl₃ film) 1285, 1459, 1678, 1740, 3484 cm⁻¹; $[\alpha]_D^{20}$ +47.5 (*c* 0.5, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 0.83 (s, 3 H), 0.86 (s, 3 H), 0.88 (t, J = 6.3 Hz, 3 H), 1.05–1.55 (m, 61 H), 1.78–1.97 (m, 4 H), 2.13 (s, 3 H), 2.36 (brs, 1 H), 2.81 (brs, 1 H), 2.95 (brs, 1 H), 3.46–3.72 (m, 8 H), 3.82–4.20 (m, 12 H), 4.33–4.47 (m, 9 H), 4.53–4.57 (m, 4 H), 4.64–4.69 (m, 2 H), 4.88 (d, J = 4.2 Hz, 1 H), 5.04 (t, J = 6.1 Hz, 1 H), 5.11 (brs, 1 H), 5.19–5.25 (m, 1 H), 5.88 (d, J = 9.4 Hz, 1 H), 7.13–7.46 (m, 36 H), 7.89 (d, J = 7.4 Hz, 2 H), 7.97 (d, J = 7.3 Hz, 2 H), 8.03 (d, J = 9.9 Hz, 1 H); ¹³C NMR (63 MHz, CDCl₃) δ 14.2, 21.1, 22.76, 22.8, 25.4, 25.8, 27.4, 27.5, 28.0, 29.46, 29.5, 29.6, 29.7, 29.76, 29.8(m), 30.0, 32.0, 32.2, 39.1, 48.7, 62.4, 63.7, 69.7, 70.3, 70.6, 71.4, 72.1, 72.5, 72.6, 73.3, 73.6, 73.7, 74.8,

75.4, 75.5, 76.9, 77.4, 79.3, 80.2, 80.4, 83.8, 85.1, 97.9, 100.6, 105.8, 127.6, 127.7, 127.9, 128.0, 128.05, 128.18, 128.2, 128.5, 128.6, 128.65, 128.7, 128.9, 133.3, 133.5, 137.2, 137.7, 138.1, 138.2, 165.3, 167.3, 170.8, 171.2. MALDI-TOF calcd for $C_{118}H_{161}NNaO_{23}$ (M+Na)⁺: m/z 1983.1357. Found: 1983.1356.

Compound S11. Compound S10 (38 mg, 0.019 mmol) was stirred under hydrogen atmosphere using a balloon in the presence of Pd/C (10%, 30 mg) in MeOH–CH₂Cl₂–AcOH (5:3:2, v/v/v, 5 mL) at room temperature for 3 h. The reaction mixture was filtered through Celite® and concentrated. The residue was purified by column chromatography on Iatrobeads® (CHCl₃/MeOH, 5:1, v/v, to 3:1, v/v) to afford the title compound S11 (23 mg, 0.016 mmol, 84%) as a colorless oil.: $R_f = 0.5$ (CHCl₃/MeOH, 3:1, v/v); IR (CHCl₃ film) 1266, 1678, 1732, 3367 cm⁻¹; $[\alpha]_D^{20} + 48.6$ (c 0.4, CHCl₃); ¹H NMR (500 MHz, CD₃OD + CDCl₃) δ 0.85 (s, 3 H), 8.6 (s, 3 H), 0.89 (t, J = 6.5 Hz, 3 H), 1.08–1.52 (m, 61 H), 1.83–2.06 (m, 4 H), 2.22 (s, 3 H), 3.56–3.77 (m, 10 H), 3.78–3.84 (m, 2 H), 3.85–3.93 (m, 3 H), 3.97 (dd, J = 4.5, 8.0 Hz, 1 H), 3.99–4.05 (m, 1 H), 4.05–4.10 (m, 1 H), 4.12 (t, J = 7.8 Hz, 1 H), 4.14–4.22 (m, 2 H), 4.71 (d, J = 3.5 Hz, 1 H), 5.01 (t, J = 6.3 Hz, 1 H), 5.04 (d, J = 4.0 Hz, 1 H), 5.19 (brs, 1 H), 5.33–5.35 (m, 1 H), 5.78 (d, J = 8.5 Hz, 1 H), 7.39–7.65 (m, 6 H), 7.92 (d, J = 7.5 Hz, 2 H), 8.01 (d, J = 7.5 Hz, 2 H), 8.32 (d, J = 9.0 Hz, 1 H); ¹³C NMR (125 MHz, CD₃OD + CDCl₃) δ 14.3, 21.0, 22.9, 23.1, 26.5, 26.1, 27.8, 28.4, 29.8, 30.1(m), 30.3,

32.3, 32.4, 39.5, 62.3, 63.7(2), 63.8(2), 68.2, 69.8, 70.2, 71.3, 71.8, 72.0, 72.6, 74.6, 75.0, 75.4, 75.7, 82.7(2), 88.4, 101.5, 101.8, 108.1, 128.9, 129.1, 129.8, 130.2, 133.8, 134.2, 166.4, 167.3, 172.0, 172.1. MALDI-TOF calcd for C₇₆H₁₂₅NNaO₂₃ (M+Na)⁺: *m/z* 1442.8540. Found: 1442.8540.


Agelagalastatin 1a (major component). A solution of compound **S11** (18 mg, 0.0127 mmol) and sodium methoxide (10 mg, 0.185 mmol) in CH₂Cl₂–MeOH (1:2, v/v, 6 mL) was stirred at room temperature for 2 h. The reaction mixture was neutralized with DOWEX CCR-3 (H⁺ mode) resin, filtered through Celite®, and concentrated. The residue was purified by washing with diethyl ether (2 × 30 mL), and concentrated in vacuo to afford the title compound agelagalastatin **1a** (14 mg, 0.012 mmol, 94%) as a colorless amorphous powder.: $R_f = 0.08$ (CHCl₃/MeOH, 3:1, v/v); $[\alpha]_D^{20} + 58.8$ (c 0.65, CH₃OH); ¹H NMR (500 MHz, C₅D₅N) δ 0.84–0.85 (m, 9 H), 1.12–1.50 (m, 57 H), 1.63–1.83 (m, 3 H), 1.87–2.08 (m, 3 H), 2.16–2.34 (m, 2 H), 4.12–4.51(m, 13 H), 4.55–4.68 (m, 5 H), 4.69–4.76 (m, 2 H), 5.14 (t, J = 8.0 Hz, 1 H), 5.23–5.26 (m, 1 H), 5.47 (d, J = 4.0 Hz, 1 H), 5.61 (d, J = 4.5 Hz, 1 H), 5.78 (brs, 1 H), 8.58 (d, J = 9.5 Hz, 1 H); ¹³C NMR (125 MHz, C₃D₅N) δ 14.3, 22.8, 22.9, 25.9, 26.5, 27.7, 28.2, 29.6, 30.0(m), 31.17, 30.2, 30.4, 32.1, 34.1, 35.6, 39.2, 51.1, 62.7, 64.4(2), 68.5, 68.9, 70.4, 71.9, 72.5(2), 72.8, 75.2, 75.5, 76.2, 79.1, 80.0, 82.5, 83.3, 88.7, 101.4, 101.7, 108.5, 175.3. HRMS (FAB) calcd for C₆₀H₁₁₅NNaO₂₀ (M+Na)⁺: m/z 1192.7910. Found: 1192.7921.





Compound S12. The title compound S12 was prepared from compound 42bα (90 mg, 0.043 mmol) in the same procedure as described for S10: 74 mg (0.00377 mmol, 88%); colorless oil, $R_f = 0.2$ (hexane/EtOAc, 1:2, v/v); IR (CHCl₃ film) 1285, 1458, 1678, 1741, 3452 cm⁻¹; $[\alpha]_D^{20}$ +45.6 (c 0.3, CHCl₃); 1 H NMR (250 MHz, CDCl₃) δ 0.84 (s, 3 H), 0.86 (s, 3 H), 0.88 (t, J = 6.3 Hz, 3 H), 1.01–1.55 (m, 61 H), 1.72–2.04 (m, 6 H), 2.13 (s, 3 H), 2.78–3.03 (m, 2 H), 3.46–3.71 (m, 8 H), 3.82–3.96 (m, 7 H), 3.97–4.03 (m, 2 H), 4.07–4.16 (m, 3 H), 4.31–4.40 (m, 6 H), 4.42 (brs, 1 H), 4.44–4.49 (m, 2 H), 4.52–4.64 (m, 4 H), 4.66–4.69 (m, 1 H), 4.88 (d, J = 4.4 Hz, 1 H), 5.03 (t, J = 6.1 Hz, 1 H), 5.13 (brs, 1 H), 5.18–5.23 (m, 1 H), 5.89 (d, J = 10.4 Hz, 1 H), 7.10–7.62 (m, 36 H), 7.89 (d, J = 7.5 Hz, 2 H), 7.97 (d, J = 7.5 Hz, 2 H), 8.09 (d, J = 9.9 Hz, 1 H); 13 C NMR (63 MHz, CDCl₃) δ 14.3, 21.1, 22.8, 25.4, 25.9, 27.4, 27.6, 28.1, 29.5, 29.9(m), 30.1, 32.1, 32.2, 39.2, 48.7, 62.5, 63.7, 69.9, 70.3, 70.6, 71.4, 72.1, 72.6, 73.3, 73.7, 74.9, 75.2, 75.5, 77.4, 79.3, 80.1, 80.4, 83.8, 84.0, 85.2, 97.9,100.5, 105.8, 127.6, 127.8, 127.9, 128.1, 128.3, 128.5, 128.8, 129.6, 129.9, 133.4, 133.6, 137.2, 137.7, 138.1, 165.4, 167.3, 170.8, 171.3. MALDI-TOF calcd for C₁₁₈H₁₆₁NNaO₂₃ (M+Na)⁺: m/z 1983.1357. Found: 1983.1360.


Compound S13. The title compound S13 was prepared from compound S12 (42 mg, 0.0214 mmol) in the same procedure as described for S11: 26 mg (0.0183 mmol, 86%); colorless oil, $R_f = 0.5$ (CHCl₃/MeOH, 3:1, v/v); IR (CHCl₃ film) 1266, 1682, 1731, 3343 cm⁻¹; $[\alpha]_D^{20}$ +49.2 (c 0.4, CHCl₃); 1 H NMR (500 MHz, CD₃OD + CDCl₃) δ 0.85 (s, 3 H), 8.6 (s, 3 H), 0.89 (t, J = 6.0 Hz, 3 H), 1.08–1.52 (m, 61 H), 1.81–2.10 (m, 4 H), 2.22 (s, 3 H), 3.57–3.77 (m, 10 H), 3.78–3.84 (m, 2 H), 3.85–3.93 (m, 3 H), 3.97 (dd, J = 4.5, 8.0 Hz, 1 H), 3.99–4.04 (m, 1 H), 4.06–4.10 (m, 1 H), 4.12 (t, J = 7.5 Hz, 1 H), 4.14–4.21 (m, 2 H), 4.71 (d, J = 3.3 Hz, 1 H), 5.00 (t, J = 6.0 Hz, 1 H), 5.04 (d, J = 4.0 Hz, 1 H), 5.19 (brs, 1 H), 5.33–5.35 (m, 1 H), 5.78 (d, J = 9.5 Hz, 1 H), 7.39–7.66 (m, 6 H), 7.92 (d, J = 7.5 Hz, 2 H), 8.01 (d, J = 7.5 Hz, 2 H), 8.33 (brs, 1 H); 13 C NMR (125 MHz, CD₃OD + CDCl₃) δ 14.3, 21.0, 22.9, 23.1, 26.7, 26.1, 27.9, 28.4, 29.8, 30.1(m), 30.4, 32.4, 32.5, 39.5, 62.3, 63.7(2), 63.8(2), 68.2, 69.8, 70.1, 71.3, 71.9, 72.0, 72.6, 74.7, 75.0, 75.4, 75.7, 82.7(2), 88.4, 101.6, 101.8, 108.1, 128.9, 129.2, 129.8, 130.2, 133.8, 134.2, 166.4, 167.4, 172.0, 172.1. MALDI-TOF calcd for C_{76} H₁₂₅NNaO₂₃ (M+Na)⁺:m/z 1442.8540. Found: 1442.8540.


Agelagalastatin 1b (minor component). The title compound **1b** was prepared from compound **S13** (16 mg, 0.0113 mmol) in the same procedure as described for **1a**: 13 mg (0.0111 mmol, 98%); colorless amorphous powder, $R_f = 0.08$ (CHCl₃/MeOH, 3:1, v/v); $[\alpha]_D^{20} + 59.8$ (c 0.45, CH₃OH); 1 H NMR (500 MHz, C_5D_5N) δ 0.84–0.85 (m, 9 H), 1.12–1.50 (m, 57 H), 1.63–1.83 (m, 3 H), 1.87–2.08 (m, 3 H), 2.16–2.34 (m, 2 H), 4.12–4.51(m, 13 H), 4.55–4.68 (m, 5 H), 4.69–4.76 (m, 2 H), 5.14 (t, J = 8.0 Hz, 1 H), 5.23–5.26 (m, 1 H), 5.47 (d, J = 4.0 Hz, 1 H), 5.61 (d, J = 4.5 Hz, 1 H), 5.78 (brs, 1 H), 8.58 (d, J = 9.5 Hz, 1 H); 13 C NMR (125 MHz, C_5D_5N) δ 14.2, 22.7, 22.9, 25.9, 26.5, 27.7, 28.2, 29.6, 30.0(m), 30.4, 32.1, 34.0, 35.6, 39.2, 51.1, 62.7, 64.4(2), 68.5, 68.9, 70.4, 71.9, 72.4, 72.5, 72.8, 75.2, 75.4, 76.2, 79.0, 80.0, 82.4, 83.2, 88.7, 101.3, 101.7, 108.5, 175.3. HRMS (FAB) calcd for $C_{60}H_{115}NNaO_{20}$ (M+Na) $^+$: m/z 1192.7910. Found: 1192.7914.



































































ppm










































































135.838 133.194 133.194 129.926 129.926 129.875 177.953 77.163 77

TBDPSO N3 0 10 10 29

